Struggles in prescribing : determinants of psychotropic drug use in multiple clinical settings by Stolker, J.J.
Struggles in prescribing:
determinants of psychotropic drug use in multiple
clinical settings
Joost Jan Stolker
Cover illustration: Bas Sebus, ‘Ecstacy’, oil on canvas, 80 x 60 cm, 2002
The picture was specially made by me for this book. It is the direct result of an
one hour brainstorm session that Joost Jan and I had on February 19th of this
year. I had an idea to start with but Joost Jan wanted pills and aggression. So
the wild horse came from me.  (I had no pictures of rodeo in my studio, but the
internet is a good catalogue). And so the picture grew into its present shape. A
man who tries to drive an excited horse with his feet in a flood of high velocity
pills.
Bas Sebus
CIP-gegevens Koninklijke bibliotheek, Den Haag
Stolker, Joost Jan
Struggles in prescribing:
determinants of psychotropic drug use in multiple clinical settings
Thesis Utrecht -With ref.- With summary in Dutch
ISBN: 90-393-3060-3
©2002 J.J. Stolker
Printed by: Bergdrukkerij, Amersfoort
Struggles in prescribing:
determinants of psychotropic drug use in multiple
clinical settings
Dilemma’s bij het voorschrijven:
determinanten van gebruik van psychofarmaca in
verschillende klinische populaties
(met een samenvatting in het Nederlands)
PROEFSCHRIFT
Ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag
van de Rector Magnificus Prof. dr W.H. Gispen ingevolge het besluit van het
College voor Promoties in het openbaar te verdedigen op dinsdag 18 juni 2002
des middags te 12.45 uur
door
Joost Jan Stolker
geboren op 20 februari 1965 te Amstelveen
PROMOTORES
Prof. dr W.A. Nolen
Brain Division, Department of Psychiatry, University Medical Center Utrecht,
Utrecht, The Netherlands
Prof. dr H.G.M. Leufkens
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute
for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands
CO-PROMOTOR
Dr E.R. Heerdink
Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute
for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands
This thesis was supported by Altrecht Institute for Mental Health Care, Den
Dolder, The Netherlands
Voor mijn ouders, Teun en Riet

Contents
1 INTRODUCTION
1.1 Scope of the thesis
1.2 Pharmacoepidemiological research in psychiatry
2 PSYCHOTROPIC DRUG USE IN PSYCHIATRIC ADMISSION WARDS
2.1 Short-acting parenteral antipsychotics drive choice for classical
versus atypical agents
2.2 Antipsychotics and seclusion in hospitalised patients: treatment
pathways
3 PSYCHOTROPIC DRUG USE IN A GENERAL INTENSIVE CARE UNIT
3.1 Determinants of psychotropic drug usage in a general intensive
care unit
3.2 Correlated measures in longitudinal analysis of daily drug use
patterns in a general intensive care unit
4 PSYCHOTROPIC DRUG USE IN SETTINGS FOR PEOPLE WITH
INTELLECTUAL DISABILITIES
4.1 Psychotropic drug use in intellectually disabled group home
residents with behavioural problems
4.2 Determinants of multiple psychotropic drug use in patients with
mild intellectual disabilities or borderline intellectual functioning
and psychiatric or behavioural disorders
5 GENERAL DISCUSSION
6 SUMMARY
7 SAMENVATTING (DUTCH)
LIST OF PUBLICATIONS
DANKWOORD (DUTCH)
CURRICULUM VITAE
9
11
25
35
37
51
65
67
79
91
93
109
121
133
141
151
153
157

CHAPTER 1
Introduction
1.1 Scope of the thesis
1.2 Pharmacoepidemiological research in psychiatry

CHAPTER 1.1
Scope of the thesis
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INTRODUCTION
The year 1952 is generally seen as the start of modern psychopharmacology
with the introduction of the antipsychotic drugs, chlorpromazine and reserpine
[1-3]. That year also saw the publication of the first reports of the anti-
depressive effect of iproniazid, a monoamine oxidase inhibitor (MAOI) derived
from isoniazid and a known tuberculostaticum [1-3]. The prescribing of
psychotropic drugs has since gained ample attention and during the ‘golden
age of drug discovery’ of the 1950s and early 1960s, there was an over-
whelming optimism about the therapeutic possibilities to treat mentally ill
patients. The first randomised-controlled trials with chlorpromazine, iproniazid
and later phenelzine were conducted during this period [1]. Many new
psychotropic compounds followed these first discoveries into clinical practice,
although from today’s standards, their therapeutic effectiveness and safety
were far from ideal. This thesis presents studies on psychotropic drug
prescribing. In the introduction, we will explore the changes in the scientific
aspects and practice of drug development that have impacted the prescribing
of psychotropic drugs.
DISCOVERY, DEVELOPMENT AND INDICATIONS OF PSYCHOTROPIC DRUGS
The process of discovery and development of drugs has changed dramatically
over the last decades [4]. The current application to register a psychotropic
drug for a specific indication is very stringent. Previously, drugs could be
registered for a variety of indications without thorough evaluation and
examples of such practice can still be found in the Dutch Repertorium of
Medicines [5]. Thioridazine was registered first in 1967 for use in patients with
psychotic disorders (Melleril®) and later in 1979 for use in low dosages in
patients with neurotic depressions (Melleretten®). In the 1960s, several
classical antipsychotic drugs, including haloperidol and zuclopenthixol, were
registered for two indications, for psychotic disorders and agitation. In contrast,
recently registered atypical antipsychotic drugs, risperidone, olanzapine and
quetiapine, are only licensed for schizophrenia.
The indications for the first psychotropic agents were discovered by serendipity.
Initial observations of  patients suffering from tuberculosis treated with
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iproniazid noted ‘euphoric’ effects and, subsequently, it was successfully tried
in patients with depression [1-3]. Imipramine was developed as an
antipsychotic because of its similarity to chlorpromazine [1-3], but it was found
to be ineffective in schizophrenic patients and in some cases, it caused manic
feelings. Imipramine was later found to be more beneficial as an anti-
depressant [6].
Following registration, many psychotropic drugs were assessed in different
patient groups in various settings. In ‘Psychofarmacotherapie’ [7], Börger and
Weijling suggested a broader spectrum of indications for psychotropics based
mostly on their own experiences, case reports in literature and open studies.
For example, chlorpromazine, diazepam, sulpiride, trifluperidol and flupen-
thixol were proposed for the treatment of anorexia nervosa; chlorpromazine,
levomepromazine, sulpiride and clorazepate were proposed for the treatment
of behavioural disorders in ‘oligophrenia’. Although, none of these
recommendations were based on the results from randomised controlled trials
(RCTs), ‘Psychofarmacotherapie’ has served as a basis for psychotropic drug
prescribing in the Netherlands for many years.
Since the 1970s and 1980s, the results of RCTs have provided evidence for the
efficacy of specific drugs for a particular indication. Liebowitz et al [8] found
that MAOI phenelzine was superior to imipramine for treating patients with
atypical depression. Nolen et al [9] reported that the MAOI tranylcypromine
was effective in depressed patients resistant to tricyclic antidepressants.
Similarly, Kane et al [10] found that clozapine was superior to chlorpromazine
in schizophrenic patients resistant to regular antipsychotics.
Psychotropics are also widely used for unregistered indications of use. Such off-
label use may be risky because the balance between safety and efficacy has not
been carefully studied [11]. Different types of off-label prescription can be
distinguished. For example, some Selective Serotonin Reuptake Inhibitors
(SSRIs) registered for depressive disorders, are unregistered for other
indications such as obsessive-compulsive disorders but are prescribed for this
purpose because other SSRIs are registered for this indication. It is also possible
that registered psychotropics are prescribed for indications without a licensed
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drug, such as SSRIs being prescribed in patients with borderline personality
disorders. Another type of off-label prescription is the use of non-registered
psychotropics: for example, tranylcypromine is widely used in the Netherlands
to treat resistant depressive disorders and only available as a so-called ‘orphan
drug’. Furthermore, patients informed by the media and internet may ask their
physician to prescribe an agent which is not well studied [11]. Physicians may
feel pressure to prescribe psychotropics to treat some disorders, despite the
lack of evidence from RCTs to support their use [12, 13]. Antidepressants, as an
example, are frequently used in bipolar depression. In contrast to the many
hundreds of RCTs studying major depression, only ten RCTs have been
conducted in bipolar depression [14]. The efficacy of an antidepressant com-
pared to placebo still remains to be proven.
CHANGES IN THE PRACTICE OF PSYCHIATRY
In the 1950s and 1960s, diagnosis did not have a high priority in psychiatry and
terms like ‘schizophrenia’ varied in meaning across different countries [15].
After a long period of psychoanalytic dominance, however, the importance of
psychiatric diagnosis was consolidated as a consequence of the flourishing of
biological psychiatry [16]. In the 1970s, the ‘Feighner Criteria’ [17] and the
Research Diagnostic Criteria [18] were developed resulting in a revision of the
Diagnostic and Statistic Manual of mental disorders: DSM-III [19]. It then
became possible to classify diagnoses according to strict criteria which,
subsequently, boosted scientific research [16]. Partly motivated by fear of a too
rigid scientific approach and as a reaction to a strong belief in biological
treatment methods, biological psychiatry and psychopharmacotherapy became
the target of criticism from the late 1960s to the early 1980s [16]. Many argued
that mental disease was a ‘product’ of social, cultural or political suffering, and
there was a strong drift away from ‘biology’ as model to understand and
approach mental illness [16]. The term ‘antipsychiatry’ was coined during this
era. The erratic prescribing of benzodiazepines, in particular, was extensively
studied and debated [20-23]. Controversies arose about the safety of these
psychotropic drugs in terms of dependence risk, falls, accidents, and
‘medicalisation’ of underlying psychological and social problems. Thus, the
climate was not very favourable for the pharmaceutical industry to invest in
the development of psychotropic drugs. This all changed in the late 1980s and
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1990s when rational drug design, evaluation and prescribing became dominant
models of thought. Although, psychiatry is frequently confronted with
difficulties in understanding aetiology, diagnosis and establishment of targets
for treatment, significant progress has been made to rationalise and give it a
scientific foundation. It has become progressively more biological over the last
decades and less conceptually isolated from the rest of medicine [24, 25].
EVIDENCE-BASED MEDICINE
In the climate of scientific, rational and biological psychiatry, evidence-based
medicine (EBM), defined as the ‘conscientious, explicit and judicious use of the
best evidence in making decisions about the care of individual patients’ became
important to the current view on mental health care [26, 27]. The practice of
EBM means integrating individual clinical expertise with the best available
external clinical evidence from systematic research. In the view of EBM, when
deciding on therapy, non-experimental approaches should be avoided as these
routinely lead to false positive conclusions about efficacy. To provide evidence-
based health care, compendia of systematic summaries of evidence-based
interventions such as the Cochrane Library, have been developed [28]. The aim
is to prepare, maintain and promote the accessibility of systematic reviews on
the effects of health care interventions [29]. However, the emphasis of EBM on
the assumption that medical interventions can always be rational and
measurable has been criticised. Faulkner and Thomas [30] mention that:
‘clinical effectiveness, if restricted to the narrow definition of ‘symptom relief’,
may fail to take into account relevant aspects of people’s lives, aspects that
may be crucial in determining an individual’s decision to continue treatment,
remain in contact with services or indeed survive’. Too great an emphasis on
EBM oversimplifies the complex and interpersonal nature of clinical care and
does not take into account the contribution of the physician’s personality and
attitude to the outcome [31, 32]. Patients may feel that their concerns are
forgotten and they are not much more than a disease being treated [30].
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THE NON-PHARMACOLOGICAL ‘CULTURE’ OF PSYCHOTROPIC DRUG
PRESCRIBING
There has been an increasing demand for the treatment of patients with
psychiatric disorders [33]. With an aging population, the risk of mental dis-
orders, such as dementia, increases [34]. Our society has become ‘multicultural’
which has also an effect on the prevalence of psychiatric disorders such as
schizophrenia [35]. A recent population study has found psychiatric disorders to
be very common in the Netherlands: the lifetime prevalence of all disorders
was 41.2%; the 12-month prevalence was 23.5%. Depression, anxiety disorders,
alcohol abuse and dependence were reported to have high prevalence and high
co-morbidity [36]. Of those 23.5% who reported having one or more psychiatric
disorders in the past year, 33.9% sought some form of professional care [37].
Various demographic characteristics were associated with individuals seeking
treatment. People with mood disorders were most likely to use professional
care and those with alcohol- or drug-related disorders were least likely to do so.
Higher educated single persons, single parents, unemployed persons, and
disabled persons were more likely to use mental health care [37].
Despite the high prevalence of psychiatric disorders, Netherlands’ general
practice has the lowest number of prescribed drugs per confirmed diagnosis
among European countries [38]. Nevertheless, there is pressure on physicians
to prescribe psychotropics more often. Additionally, there is a shortage of beds
for severely disturbed patients and patients are discharged from admission
wards sooner than before [39].  Furthermore, in our ‘poldermodel’ culture [40],
patients and family members informed by the media, internet, patient or
family associations frequently pressure the physician into prescribing
psychotropic drugs. Nurses, caring for a patient and facing his or her problems
for many hours a day, can also sometimes urge the physician to prescribe
medications.
National differences related to cultural values exist in the use of psychotropics
within Europe. Compared to other European countries, the Netherlands has low
consumption and costs of medicines [41]. However, use of psychotropic drugs
expressed in number of prescriptions increases. For example, the use of
antidepressants from 1999 to 2001 increased by 17% in the Netherlands, as
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compared to 22% and 2.5% in Spain and Germany, respectively (IMS Health BV,
personal communication, 2002). Germany uses significantly less tranquillisers
and more herbal remedies than the rest of Europe [42, 43].
Regional differences in the use of psychotropics exist within the Netherlands.
Egberts et al [44] found that although the same five antidepressant drugs,
namely amitriptyline, clomipramine, fluoxetine, fluvoxamine and paroxetine,
were among the most frequent first prescriptions, the ranking of these drugs
differed between the northern and southern regions of the country. The
process of prescribing an antidepressant drug for first time users was
influenced primarily by regional preferences and less determined by patients
characteristics, such as gender and prescriber (general practitioner or
specialist). These variations likely pertain to different regional guidelines for the
use of psychotropics and to promotional activities of pharmaceutical industries.
Good health and belief in the autonomy of the patient are important values in
the Western world [45]. Patients demand to be informed about their medicines
by their physician and pharmacist [46]. Information on psychotropic drugs and
psychiatric disorders is easily accessible from the media, internet and patient
societies, and personal experiences of psychiatric disorders are publicly
expressed. It is generally known that Prince Claus, Queen Beatrix’s husband,
suffers from a depressive disorder. The Dutch psychiatrist Prof P.C. Kuiper wrote
a book about his own depression [47]. The British Princess of Wales, Diana
spoke about her eating disorder in a television interview, and the Dutch
newspaper columnist, Emma Brunt, reported on her own depression and its
successful treatment with antidepressants after years of psychotherapy  [48].
Alongside this celebrity openness, the 1990s hype of the antidepressant Prozac
was another factor contributing to the de-stigmatisation of psychiatric
disorders [16]. Kramer [49] coined the term ‘cosmetic psychopharmacology’ in
his book ‘Listening to Prozac’. He suggested that SSRIs may be used to improve
personality traits in normal individuals, without a formal psychiatric diagnosis.
‘Cosmetic psychopharmacology’ may lead people not suffering from psychiatric
disorders but from normal unpleasant feelings of anxiety and dysphoria to seek
to relief from their problems with psychotropics, like fluoxetine (Prozac®) and
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see their physician as supplier of drugs [16]. Kramer’s book has been criticised
but it also inspired researchers to think seriously about issues, such as the
relationship between personality and depression [50].
OBJECTIVES OF THE THESIS
The reality of clinical practice may appear to be ‘at odds’ with official
registrations and the results from RCTs. Studying determinants of psychotropic
drug use may help to explore the gap between clinical practice and evidence.
The primary objectives of this thesis are to assess the prevalence of
psychotropic drug use and analyse possible determinants associated with its
use in four clinical settings. The four settings are characterised by a
heterogeneous population of patients with psychiatric and somatic co-
morbidity. In the admission wards, nearly all hospitalisations are acute, and
many patients are involuntarily admitted. In the intensive care settings, co-
morbid (organic) psychiatric disorders are frequently seen in somatically ill
patients with severe internal diseases or in those following surgical inter-
ventions. In the homes for the intellectually disabled, behavioural problems
occur frequently. In the specialised psychiatric unit for intellectually disabled,
only severely ill patients who cannot be treated elsewhere are hospitalised here
as a last resort.
In the following section of the introduction (Chapter 1.2), we highlight methods
used in pharmacoepidemiology, consider differences between randomised
controlled trials and observational research, and discuss possibilities and
limitations of these methods in psychiatric research.
Chapters 2, 3 and 4 present the empirical findings of this thesis. In Chapter 2.1,
we investigate the selection of antipsychotic drugs (classical versus atypical)
prescribed in a psychiatric hospital. Factors associated with choosing between
the two classes of antipsychotics for the treatment of newly admitted patients
on acute psychiatric wards are explored. In Chapter 2.2, the results of a study
on the association between antipsychotics and seclusion are presented.
Chapter 3.1 focuses on the association between patient-related factors and
psychotropic drug use in an intensive care unit for somatically ill patients. In
Chapter 3.2, the methods used in the intensive care study are first examined
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and then compared to different study designs. Chapter 4 reports on the
analyses on the use of psychotropic drug in a population of intellectually
disabled patients. In Chapter 4.1, results of a study on psychotropic drug use
among residents of group homes with behavioural problems compared to a
randomly selected group of residents are presented. In Chapter 4.2,
determinants of multiple drug use are studied at a specialised unit of a
psychiatric hospital.  A discussion of all our studies, with implications for
research and clinical practice, is presented in Chapter 5.  Chapter 6 provides a
summary of this thesis.
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ABSTRACT
Because of the strict in- and exclusion criteria applied in randomised controlled
trials (RCTs), the populations participating in RCTs differs greatly from daily
practice and therefore effectiveness of a drug in daily practice can only be
limitedly predicted. Pharmacoepidemiological research is very helpful to get
additional information. In this Chapter we discuss the methods used in
pharmacoepidemiology, consider the differences between randomised
controlled trials and observational research and discuss the possibilities and
weaknesses of pharmacoepidemiological research in psychiatry. Pharmaco-
epidemiology makes it possible to get additional insights into effectiveness and
safety of psychotropics in clinical practice.
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INTRODUCTION
Psychiatry has gone through major changes during the second half of the last
century, mainly due to the advent of psychopharmacology. The increasing
number of patients on psychotropics can be investigated through pharmaco-
epidemiological research, in which patterns of use and the effects of the drugs,
both adverse and beneficiary, may be studied in daily practice.
In this Chapter we will discuss the methodology of this type of research,
consider the differences between the randomised controlled trial (RCT) and
observational research and discuss the possibilities and weaknesses of
pharmacoepidemiological research in psychiatry. We will illustrate this through
a number of studies that will be presented throughout the Chapter.
WHAT IS PHARMACOEPIDEMIOLOGY?
In 1961, the New Zealand physician McBride published a letter in The Lancet in
which he reported his observation that an unexpectedly large number of
congenital abnormalities were found in children from mothers that had used
the hypnotic thalidomide [1]. Until then this drug had been promoted as a safe
alternative to the barbiturates. McBride's publication can be seen as a
breakthrough in the thinking about the need for continuous evaluation of
quality, effectiveness and safety of drugs after marketing. While (pharmaco-
logical) efficacy and safety of a drug must be proven before its registration, very
little is known on the use, effectiveness and safety of a drug in daily clinical
practice at the time of registration. In 1984, Lawson coined the term
pharmacoepidemiology for the science that bridges clinical pharmacology and
epidemiology [2]. Pharmacoepidemiology studies the use and the effects of
drugs in large populations, including determinants of use while its most
important characteristic is its observational nature in which it fundamentally
differs from pre-registration RCTs.
OBSERVATIONAL RESEARCH AND RANDOMISED CLINICAL RESEARCH
For registration purposes, the RCT is considered to be the 'Golden Standard'. In
an RCT, relatively few carefully selected patients are randomly assigned to an
experimental group and to one or more control groups. Limited conclusions on
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the effects of drugs in daily practice can be drawn from the results of such
RCTs. Through selection of patients for RCTs large discrepancies arise between
the populations participating in a RCT and those who are prescribed the drug
directly following marketing [3]. Participants in RCTs are more often young,
male, have a less severe disease status and less co-morbidity and co-medication
and show a better therapy compliance compared to patients in daily practice
[3]. Moreover, newly registered drugs have to compete with existing drugs for
similar indications. This may result in a marked selection of patients to whom
new drugs are prescribed, e.g. patients who are therapy resistant or who have
experienced adverse effects with previous therapy.
Large scale observational studies offer better generalisability of results into
daily clinical practice. The major disadvantage is that treatments are not
randomised, which may influence the comparison between drugs resulting in
differences in outcomes that are inadvertently attributed to the use of a certain
drug. This is illustrated in a study in which 228 psychiatrists and general
physicians filled in a questionnaire on indications of antidepressants [4]. It was
found that clomipramine and amitriptyline were most often prescribed for
major depression and other diseases including anxiety disorders and pain.
Antidepressants with a known lower toxicity in overdose (such as moclo-
bemide) were more often prescribed to patients with suicidal tendencies. If this
is not taken into account in pharmacoepidemiological analysis, this could lead
to the (most likely incorrect) conclusion that there is an association between
moclobemide and suicide.
APPLICATIONS OF PHARMACOEPIDEMIOLOGICAL RESEARCH
Evaluation of (un)known adverse effects
In Table 1 the most important applications of pharmacoepidemiological
research are listed. Adverse events are often not detected in the relatively small
and highly selected populations included in RCTs, especially when the adverse
event is rare and/or occurs only after long term use. This is why registration
authorities request physicians and pharmacists to report unknown and serious
adverse events of marketed drugs. In most European countries these
spontaneous adverse drug reaction reporting systems are based on voluntary
action. A recent example of the evidence from spontaneous reporting systems
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are the reports from the Swedish Adverse Reactions Advisory Committee
suggesting that clozapine is associated with venous thromboembolic
complications [5, 6]. In another example, cases of non-puerperal lactation
associated with antidepressant drug use reported to a spontaneous adverse
drug reaction programme in the Netherlands were evaluated [7].
Table 1. Applications of pharmacoepidemiological research -adapted from Strom- [8].
More insight in:
• (Un)known adverse effects
− in a normal population
− in a population not studied prior to marketing (elderly, children, pregnant
women, patients with comorbidity, non-compliant patients, etc.)
− in cases of drug overdoses
− in cases of drug interactions
• The use of drugs in daily practice
• Characteristics of a drug compared to other drugs with a similar indication
• Pharmacoeconomic aspects
Post marketing surveillance (PMS) is a form of pharmacoepidemiological
research defined as the monitoring of and scientific study into all adverse and
beneficiary effects of marketed drugs. PMS studies have been widely criticised
[9-12]. When sponsored and conducted by pharmaceutical industry, they are
sometimes misused for marketing purposes. A British group of academic
researchers, government, and pharmaceutical industry have developed
guidelines for the Safety Assessments of Marketed Medicines (SAMM
guidelines) listed in Table 2 [13].
Besides government and pharmaceutical industry, clinicians are interested in
differences in effects of drugs in daily practice. This is illustrated by a recent
study conducted in a population of 39,807 antidepressant users identified in a
prescription database in Denmark [14]. Users of tricyclic antidepressants had
an excess of non-Hodgkin's lymphoma, with the risk increasing with the
number of prescriptions of tricyclic antidepressants. The standardised incidence
ratio was 2.5 (95% confidence interval: 1.4-4.2) for those with five or more
prescriptions.
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Table 2. Safety of Marketed Medicines (SAMM) guidelines [12].
• The research population must be as representative as possible of the general
population of users.
• The prescribing of a drug and the inclusion of the patient in a study are two issues
which must be clearly separated. The drug should be prescribed in the usual
manner.
• An appropriate comparator group must be included.
• Patients must not be prescribed particular medication in order to include them in
a study.
• The number of patients to be entered by a single doctor is limited. No patient
should be entered into more than one study simultaneously.
• The study should not be conducted for the purposes of promotion.
• The doctor receives only payment in recompense for his time and any expenses
incurred.
The use of drugs in daily practice
Drug utilisation in daily practice is exemplified by a study into the actual use of
antidepressants [15]. Prescribing patterns of antidepressants were analysed
using data of insurance claims. It was shown that over 50% of the patients used
antidepressants for fewer than 4 months. Also, the average daily dosages were
significantly lower than the recommended dosages in depression. The
conclusion of this study was that a substantial part of patients was not
adequately treated.
For large scale observational studies it is important to establish large databases
containing information on drug use. During the last decades, a number of these
databases linking drug prescription data to clinical data have been developed
with their own individual strengths and weaknesses. For example, in the USA
data of the Kaiser Permanente Medical Care Program are used for
pharmacoepidemiological studies [16]. In Canada, the Sasketchewan Health
Databases have been developed and in the UK the Tayside Medicines
Monitoring Unit [17, 18]. In the Netherlands, the PHARMO database system
was been used for research purposes since the early nineties [19]. For example,
in a study into benzodiazepines and the risk of falling leading to femur
fractures among patients of 55 years or older, this database was used [20]. It
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was seen that the use of benzodiazepines is an important risk factor for falls
leading to these fractures probably explained by prescribing too high doses.
Characteristics of a drug compared to other drugs with a similar indication
When a drug is newly registered, one wants to know how the effects of the
drug in daily practice compares to drugs that are already available for the same
indication. In pharmacoepidemiological research patients on a certain drug
may be compared to patients on another drug for the same indication. Various
outcomes that can be studied include safety aspects (the occurrence of adverse
effects, the use of co-medication for the treatment of possible adverse effects
and hospitalisations), effectiveness (reduction of symptoms, duration of use
and recurrence of disease) and drug utilisation/prescribing patterns (patient
questionnaires, ease of use and compliance). For example, in a recent study the
prescribing of TCAs versus SSRIs in elderly patients was evaluated through
measurement of adverse effects and the severity of depressive disorder [21].
Pharmacoeconomic aspects
During the last years, pharmacoeconomic aspects in prescribing have become
more and more important. Many studies into these aspects are based on RCTs
with a retrospective calculation of the costs in which determinants are
associated with the use of the drug [22, 23]. These methods have serious
limitations in their applicability to real-life data [24].
An example of a pharmacoeconomic study not using data of an RCT is a study
into the 1-year total direct health care costs for patients initiating therapy with
TCAs compared with SSRIs [25]. Data from fee-for-service private insurance
claims in the USA were used. The 1-year total direct health care costs were
found to be lower for patients initiating therapy on fluoxetine compared to
patients initiating therapy on a TCA and lower for patients who initiated
therapy on fluoxetine than for patients initiating therapy on sertraline. The
authors conclude that the findings of the study suggest that total direct health
care costs differ across initial antidepressant selection.
In conclusion, RCTs are essential to demonstrate efficacy of new drugs, but
pharmacoepidemiological research makes it possible to get additional insights
in effectiveness and safety of psychotropics in clinical practice.
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ABSTRACT
The introduction of atypical antipsychotics has changed treatment options for
psychotic disorders dramatically. There has been a large shift favouring the use
of atypical antipsychotic agents, although their precise therapeutic value
remains controversial. The objective of this study was to investigate the factors
affecting the choice of antipsychotic agents (classical versus atypical) given first
to newly hospitalised patients. A nested case control study was conducted in a
cohort of 522 patients treated with an oral antipsychotic drug. Recipients of an
atypical agent were considered as cases (27.8% of patients). Controls were all
other cohort members. No statistically significant difference was found
between patients suffering varying degrees of disease severity. Patients treated
with classical oral antipsychotics had more often received short-acting
parenteral antipsychotics earlier than patients treated with atypical
antipsychotics (40.8% versus 15.2%) (adjusted odds ratio: 0.14; 95% confidence
interval: 0.07-0.29). Availability of injectable forms seems to be a major factor
in the choice of oral agents later prescribed for psychosis. Thus, future
introductions of short-acting parenteral atypical formulations are likely to have
a large impact on the choice of oral treatments prescribed for psychosis.
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INTRODUCTION
Antipsychotic drugs are essential in the treatment of patients suffering from
psychotic disorders, both in clinical and community settings [1]. Over 20 drugs
with varying pharmacological properties are currently available for treatment
of psychotic disorders. Classical or typical antipsychotic drugs, including
haloperidol and pimozide, are widely used as first-line treatment for psychotic
disorders, in acute as well as in chronic forms of the illness [2]. However, these
substances have a relatively limited effect on negative symptoms associated
with schizophrenia, i.e. lack of speech, lack of motivation, apathy and inability
to express emotions [3]. Moreover, their use is associated with adverse effects,
including extrapyramidal symptoms (EPS) often resulting in non-compliance or
premature discontinuation  [4, 5].
The introduction of atypical antipsychotics (clozapine, olanzapine, risperidone,
quetiapine and ziprasidone) has changed treatment options for psychotic
disorders dramatically. There has been a large shift favouring the use of these
atypical antipsychotic agents [6], although their precise therapeutic value
remains controversial [7-13]. Their effect on negative symptoms is not fully
elucidated. Newer agents seem to be superior with regard to risk on EPS, but
they have been associated with other side effects, such as weight gain [14].
Official therapeutic guidelines, including the one on the pharmacotherapy of
psychotic disorders in the Netherlands [15], have not yet decided between
classical or atypical antipsychotics as first-line treatment. For insight into
prescribing patterns of these drugs in daily practice and factors that affect the
choice between classical and atypical antipsychotics, an observational study
within a well-defined group is needed.
The objective of our study was to investigate which class of antipsychotic drugs
(classical versus atypical) is used preferentially in newly admitted psychiatric
patients and the determinants affecting this choice.
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METHODS
Setting and study population
Data were retrospectively collected from the acute psychiatric admission wards
of three psychiatric hospitals, serving a catchment area of about 720,000
inhabitants in the centre of the Netherlands, during 1997-1999. Patients, aged
between 18 and 60 years, who were admitted for a new hospitalisation of at
least 3 days were included in the cohort. 'Newly hospitalised' was defined as
having no previous admission to the psychiatric centre for any indication in the
2 years before the inclusion date. We reviewed data from 1995 for the 1997
admissions.
Design
In a retrospective cohort design, patients were followed from date of admission
until discharge from the hospital. In the cohort of newly admitted patients
treated with an oral antipsychotic drug, a nested case control study was
conducted considering recipients of an atypical agent as cases. Controls were
all other cohort members.
The drug use database and the clinical database were linked anonymously
through record linkage methodology based on date of birth, gender and date of
admission [16]. At admission, diagnoses were coded according to DSM-IV [17]
criteria by the treating psychiatrists. Patients were rated on the Global
Assessment of Functioning (GAF), with a low GAF score denoting more severe
illness. The admission wards were classified as ‘open’ or ‘closed’. Closed wards
have limited access after admission and are reserved for more severely ill
patients.
All medication was classified according to the ATC-classification system [18].
Antipsychotics (ATC-code N05A) were classified as classical or atypical. Lithium,
levomepromazine and promethazine are not registered for psychotic disorders
in the Netherlands and were, therefore, excluded. Clozapine, olanzapine,
risperidone, sertindole and quetiapine were classified as atypical
antipsychotics; other drugs with 4 digits ATC-code N05A were classified as
classical antipsychotics. Drugs were also stratified according to their route of
administration: oral or parenteral. We differentiated between parenteral short-
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acting (e.g. haloperidol- and zuclopenthixol-acetate) and long-acting (depot)
antipsychotics. We excluded 31 patients who either received both an oral
classical and atypical antipsychotic on the day of admission or received only
depot antipsychotics.
The Scientific Committee and the board of the Centre for Mental Health
approved the study protocol with respect to privacy aspects.
Analysis
The overall utilisation patterns of oral antipsychotics over time were
ascertained by calculating the prevalence of drug use on the second
Wednesday of each quarter between 1997 and 1999. The incidence of new
antipsychotic drug users was also calculated for each quarter. We calculated
the relative incidence and prevalence for both classes by expressing the values
as percentages of total antipsychotic drugs used.
Odds ratios were calculated for factors possibly associated with the choice
between classical versus atypical antipsychotics (age, gender, all DSM-IV
diagnoses, use of short-acting parenteral antipsychotic, GAF score and type of
ward). Logistic regression was used to adjust for possible confounders (age
group, gender, DSM-IV diagnoses, use of short-acting parenteral antipsychotic).
Data were analysed using EGRET statistical software.
RESULTS
The characteristics of the cohort members are presented in Table 1. A total of
522 patients met the inclusion criteria. Most patients (60.9%) were younger
than 40 years with a median age of 36 years. Psychotic disorders accounted for
50.2% of the diagnoses of the patients admitted. Other diagnoses included
bipolar (16.3%), depressive (12.6%), and personality disorders (16.7%). The most
frequently prescribed oral antipsychotic drugs were zuclopenthixol (33.7%),
pimozide (13.4%) and haloperidol (12.6%). The proportion of atypical agents
was 27.8%, consisting of clozapine (1.9%), olanzapine (14.8%) and risperidone
(11.1%). While the total proportion of incident prescriptions of atypical
antipsychotics increased only slightly from 27.2% to 35.1%, initial prescription
of olanzapine increased over the years 1997 until 1999 from 7.8% to 19.6%.
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Table 1. Characteristics of 522 newly admitted patients using antipsychotics.
n (%)
Age (years)
  <40
  ≥40
  Median
Gender
  Male
  Female
Any diagnosis (DSM-IV)*
  Schizophrenia and psychotic disorder
  Bipolar disorder
  Depressive disorder
  Other
  Unknown
318 (60.9%)
204 (39.1%)
36
273 (52.3%)
249 (47.7%)
262 (50.2%)
85 (16.3%)
66 (12.6%)
23 (4.4%)
65 (12.5%)
A third of patients was initially treated with a short-acting parenteral
antipsychotic drug. A vast majority of this group (94%) was treated with
zuclopenthixol-acetate, a parenteral formulation that acts for 2-3 days.
Figure 1 depicts the ratio between incident users of classical versus atypical oral
antipsychotics in each 3-month period from January 1997 to December 1999. The
proportion of users starting an atypical antipsychotic was stable at around 30%. In
the same figure, the proportion of prevalent use of classical and atypical oral
antipsychotics over time is depicted. The fraction of oral atypical antipsychotic use
increased between 1997 and 1999 from 28.8% to 44.3% in relation to the total
amount of oral antipsychotic use.
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Figure 1. Relative incidence and prevalent use of oral classical and atypical
antipsychotics 1997-1999.
In Table 2, possible determinants of type of first oral antipsychotic use are
listed. We found that 154 (40.8%) out of 377 patients treated with classical oral
antipsychotics were initially treated with short-acting parenteral formulations.
This was 15.2% in the group treated with an oral atypical antipsychotic
(adjusted odds ratio: 0.14; 95% confidence interval: 0.07-0.29). The use of
atypical agents was significantly lower in patients with bipolar disorders
(adjusted odds ratio: 0.30; 95% confidence interval: 0.11-0.80). No statistically
significant difference was found between patients with varying severity of
disease, indicated by GAF score and type of ward (open versus closed). GAF
scores were missing in 180 (34.4%) patients. Analysis revealed that most
missing GAF scores were from the 1997 admissions, in which 64.6% of GAF
scores was missing, while in 1998 and 1999, 13.6% and 26.3% were missing,
respectively.
% atypical: incidence
% classical: incidence
% atypical: total
% classical: total
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
97-1 97-2 97-3 97-4 98-1 98-2 98-3 98-4 99-1 99-2 99-3 99-4
44•  CHAPTER 2.1
Table 2. Factors associated with choice of  first oral antipsychotic (N = 522). Crude odds ratios and
adjusted odds ratios with 95% confidence interval (95% CI) of atypical antipsychotics compared to
classical antipsychotics. Significant associations are printed in bold.
Atypical
antipsychotics
(n = 145) (%)
Classical
antipsychotic
(n =377) (%)
Crude odds
ratio  (95% CI)
Adjusted odds
ratio (95% CI)
Age
  <40
  ≥40
96 (66.2)
49 (33.8)
222 (58.9)
155 (41.1)
1.0 (reference)
0.7 (0.5-1.1)
1.0 (reference)
0.8 (0.4-1.4)
Gender
  Male
  Female
81 (55.9)
64 (44.1)
192 (50.9)
185 (49.1)
1.0 (reference)
0.8 (0.6-1.2)
1.0 (reference)
0.74 (0.42-1.30)
Initial short-act. parent.
antipsychotic 22 (15.2) 154 (40.8) 0.3 (0.2-0.4) 0.14 (0.1-0.3)
DSM-IV diagnosis *
  Psychotic disorder
  Bipolar disorder
  Depressive disorder
  Personality disorder
  Anxiety disorder
  Other disorder
  Unknown disorder
78 (53.8)
9 (6.2)
18 (12.4)
21 (14.5)
7 (4.8)
8 (5.5)
25 (17.2)
184 (48.8)
76 (20.2)
48 (12.7)
66 (17.5)
19 (5.0)
15 (4.0)
40 (10.6)
1.2 (0.8-1.8)
0.3 (0.1-0.5)
1.0 (0.5-1.7)
0.8 (0.5-1.4)
1.0 (0.4-2.3)
-
-
1.19 (0.6-2.4)
0.30 (0.1-0.8)
0.65 (0.3-1.7)
0.48 (0.2-1.1)
0.55 (0.2-1.9)
-
-
Global Assessment
of Functioning (GAF)
  <35
  35-55
  ≥ 55
  Missing GAF
33 (22.8)
43 (29.7)
15 (10.3)
54 (37.2)
99 (26.3)
127 (33.7)
25 (6.6)
126 (33.4)
1.0 (reference)
1.0 (0.6-1.7)
1.8 (0.9-3.8)
-
1.0 (reference)
1.06 (0.6-1.9)
1.78 (0.8-4.1)
-
Type of ward
  Open ward
  Closed ward
49 (33.8)
96 (66.2)
100 (26.5)
277 (73.5)
1.0 (reference)
0.71 (0.5-1.1)
1.0 (reference)
0.73 (0.4-1.4)
*Totals may exceed 100% because of multiple diagnoses.
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DISCUSSION
We found that a stable proportion of patients was started on atypical oral
antipsychotics during the study period. About one third of all new antipsychotic
users received an atypical agent. We noted an increase in the use of atypical
antipsychotics which means that patients were either using atypical agents for
longer periods of time, or were more often switched from classical to atypical
agents than vice versa.
Patients with psychotic illnesses may have delusions or hallucinations that may
lead them to be aggressive or violent to themselves or others. Medication that
is used in this context requires the property of a rapid onset of effect
(tranquillisation or at least initial sedation in order to control aggressive or
disorganised behaviour) [19]. An antipsychotic effect is also needed, but cannot
be expected within one or two weeks. In this context, it is an unexpected
finding that our two markers of disease severity, GAF scores and type of ward
(open or closed) of patients receiving oral atypical agents did not differ from
those treated with oral classical agents, suggesting that severity of disease is
not a determinant for the choice of drug used between these patient groups.
This study showed that availability of injectable forms seems to affect the
selection of the follow-up oral antipsychotic agent. Seven times as many
patients treated with oral classical agents compared to oral atypical agents
were initially treated with short-acting parenteral agents. The choice for one of
the available injectable forms with immediate action, frequently done in a
situation when rapid response to a psychotic crisis is needed, affects follow-up
treatment scenarios, assuming the administration of an antipsychotic drug
results in a positive effect (e.g. control of aggression) on the acute status of the
patient. As a result, the physician will often choose to continue the same type
of medication in an oral formulation. Choice of the follow-up oral medication
seems to express the satisfaction of the effect of the short-acting parenteral
antipsychotic on the non-psychotic symptoms.
At the time of this study, Dutch guidelines for prescribing antipsychotics in
schizophrenic psychosis [15] have not yet decided between classical and
atypical agents for first-line treatment. In our three study hospitals, no financial
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or administrative barriers were made to prevent physicians from prescribing
new and expensive atypical antipsychotics. In literature, the debate on choice
for first-line treatment of psychosis is also still ongoing. In a recently published
meta-analysis studying 52 randomised-controlled trials of atypical
antipsychotic drugs in the treatment of schizophrenia, Geddes et al [8]
concluded that atypical agents are not better tolerated than typical agents.
They recommended that classical antipsychotics should be the first-line
treatment for schizophrenia. This same review has, however, been extensively
criticised, arguing that for the majority of patients atypical antipsychotics
should be used as first-line drugs [20-26].
We found a large difference between the initial use of classical and atypical
antipsychotics in bipolar disorders although the Dutch guidelines for
pharmacotherapy of these disorders are inconclusive [27].
There are some limitations to our study. Although one could argue that only
data on admitted patients were available, we were, however, interested in the
more severely ill patients who were admitted to a psychiatric hospital. Another
limitation is the possibility that our selection of newly admitted patients may
contain some patients previously admitted in another region before moving to
the catchment area of our hospital. Since patients in the Netherlands are
preferably transferred to their home region, this would only apply to a minority
of the included patients. Although we collected data from only three hospitals,
their catchment area is very large and admission in most cases would lead to
admission to one of the investigated hospitals.
More than 30% of GAF scores were noted to be missing, with the most missing
scores connected to the 1997 admissions when it was not yet common practice
to record GAF scores into the hospital database. More attention was given to
this subject in 1998 and 1999. We found that patients with available GAF
scores did not differ in gender, age and only slightly in diagnostic categories
when compared to patients with missing GAF scores. It is, therefore, likely that
our data are representative for the total population of patients. The other
marker of disease severity (type of ward) also showed the same sort of result.
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Parenteral formulations of only classical antipsychotic agents are presently
available. Our study reveals that initial use of short-acting parenteral
antipsychotics is (also after adjusting for possible confounding factors) a major
determinant for the choice of the follow-up oral treatment. We anticipate that
upcoming introductions of short-acting parenteral formulations of atypical
agents are likely to have a large impact on the follow-up oral antipsychotic
treatment. Because of much higher pricing of atypical antipsychotics, a shift in
favour of the atypical antipsychotics would also be expected to have a major
effect on hospital budgets. Another investigation of the determinants affecting
the selection of oral antipsychotics may be warranted after introduction of a
short-acting parenteral formulation of an atypical agent.
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ABSTRACT
Seclusion is one of the strategies to cope with disruptive and violent behaviour
in psychiatric patients. Situational factors including psychotropics in relation to
seclusion have hardly been studied. We wanted to identify possible
determinants of seclusion and gain insight into the temporal relationship
between seclusion and the use of antipsychotics in newly admitted patients.
Data were retrospectively collected for the years 1997-1999 from a consecutive
sample of 996 patients from adult psychiatric admission wards. In a nested
case-control analysis, secluded and non-secluded patients were compared. In
another analysis, patients were followed from admission to a week after the
first seclusion. We found that young age, low GAF score, involuntary
hospitalisation and bipolar disorder (manic episode) were significantly
associated with seclusion, applicable to 28.6% of the patients. Antipsychotic
treatment early in the hospitalisation was associated with a delay of seclusion
and, although not statistically significant, with a lower risk of seclusion. In a
substantial part of the population, antipsychotic treatment was initiated
during or shortly after seclusion. In conclusion, (forced) pharmacological
treatment appears inevitable for a substantial proportion of secluded psychotic
patients. It is likely that earlier use of antipsychotics may prevent patients from
being secluded.
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INTRODUCTION
In psychiatric inpatient care, seclusion is one of the strategies to cope with
disruptive and violent behaviour [1-3]. Compared to the relatively large number
of studies on the characteristics of secluded patients, situational factors in
relation to seclusion have hardly been studied [3, 4]. Remarkably, this is also the
case for the relationship between psychotropics and the application of
seclusion. In the Netherlands, involuntary hospitalisation does not mean that
patients can be treated pharmacologically against their will. Special treatment
methods, such as seclusion and involuntary medication, may only be applied in
involuntarily hospitalised patients, in case of serious danger to the patient or
others, with the exclusion of emergencies.
In the current study of hospitalised patients on acute admission wards, we
sought to identify determinants of seclusion and to investigate the temporal
relationship between seclusion and the use of antipsychotics.
MATERIALS AND METHODS
Patients and data collection
Data were retrospectively collected from a consecutive sample of 996 patients
aged 16 years or older concerning their first complete hospitalisation of four
days or longer in one of the participating admission wards during 1997-1999.
The admission wards with a total of 250 beds are part of three general
psychiatric hospitals in the centre of the Netherlands, recently merged to one
large institute for mental health care with a total catchment area of 720,000
persons. Patient characteristics, data on the use of seclusion and antipsychotics
were extracted from the patient database and a linked automated database of
the pharmacy. The Scientific Committee and the board of the Centre for Mental
Health approved the study protocol with respect to privacy aspects.
Databases
The hospital patient database contains demographic data, diagnoses,
admission and discharge dates, and data on seclusion. In the automated
pharmacy database, every initiation and subsequent change in the prescription
of medication is recorded. Both databases contain information on date of birth,
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gender and date of admission, allowing the two databases to be linked
anonymously. In a validation study, the linkage success of 150 randomly
selected patients was greater than 95%.
Psychiatric diagnosis and antipsychotic treatment
At admission, (multiple) psychiatric diagnoses were established by the
psychiatrists on the wards according to DSM-IV criteria [5] (schizophrenia and
other psychotic disorders, substance-induced psychotic disorders, depressive
disorders, anxiety disorders, bipolar disorders, personality disorders). Patients
were rated on the Global Assessment of Functioning (GAF), with a low GAF
score denoting more severe illness.
Medication was coded according to the WHO Anatomical Therapeutic Chemical
(ATC) coding system. Data on antipsychotics (ATC-code N05A) were collected,
excluding droperidol, levomepromazine and promethazine that are mainly
prescribed for sedation in the Netherlands and lithium that is mainly used as a
mood stabiliser.
Data Analysis
In the nested case-control analysis, secluded patients were compared to non-
secluded patients. Odds ratios were calculated to evaluate the possible effects
on seclusion of age, gender, (in)voluntary hospitalisation, psychiatric diagnosis
and GAF score. Unconditional logistic regression analysis was used. All
seclusions were included in this analysis.
In the follow-up analysis, patients were followed from admission to a week
after the first seclusion, or from admission to a week after an index date at a
proportional point in time during hospitalisation. Patients, secluded
immediately at the time of admission, were excluded because no data on
medication use prior to seclusion were available for these patients. We
analysed time from the admission date to the first seclusion comparing
patients with and without using antipsychotics in the first week of
hospitalisation. Hazard ratios were calculated using Cox proportional hazards
survival analysis. Relative risks were calculated for patients using
antipsychotics in the first week of hospitalisation prior to seclusion compared
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to non-users. Relative risks were calculated for patients not using
antipsychotics prior to seclusion and starting antipsychotics during, or shortly,
after seclusion compared to non-secluded patients using antipsychotics. All
analyses were performed with SPSS Package and EGRET.
RESULTS
Basic characteristics
The mean age of the population of 996 patients was 38.0 years (median: 37.0
years; range: 16-84 years). The number of male patients, 507 (50.9%), was
almost equivalent to the number of female patients. The mean duration of
hospitalisation was 57.2 days (median: 24.0 days; range: 4-711 days). Psychotic
disorders were most prevalent: 398 of the 996 patients (40.0%). Little more
over a quarter of the patients (i.e. 285 of 996 patients or 28.6%) had been
secluded at least once during their hospitalisation.
Patient-related factors associated with seclusion
In Table 1, possible factors associated with seclusion are listed. Young age was
significantly associated with seclusion as was a lower GAF score between 35-55
and below 35, indicating major impairment in functioning. Involuntarily
hospitalised patients were more likely to be secluded than voluntarily
hospitalised patients with an odds ratio of 4.9 (95% confidence interval: 3.5-
6.9). Of the psychiatric diagnoses, only bipolar disorder (manic episode) was
significantly associated with seclusion.
Time to seclusion
The mean time from admission to seclusion among patients with psychotic
disorders who used antipsychotics during the first week was 21.6 days (median:
7.0 days; range 1 to 235 days). In patients not using antipsychotics this was
15.2 days (median: 2.5 days; range 1 to 213 days). Figure 1 shows a Kaplan-
Meier plot during the first month of hospitalisation in this population. We
found that antipsychotic use was significantly associated with a delay of
seclusion with an adjusted (gender, age, GAF score) hazard ratio of 0.6 (95%
confidence interval: 0.3-1.0).
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Table 1. Factors associated with seclusion in hospitalised patients (N = 996). Crude odds ratios and
adjusted* odds ratios with 95% confidence interval (95% CI) of secluded patients compared to non-
secluded patients. Significant associations are printed in bold.
Secluded
(n = 285) (%)
Non-secluded
(n = 711) (%)
Unadjusted Odds
Ratio (95% CI)
Adjusted Odds
Ratio (95% CI)
Gender
  Female
  Male
119 (41.8)
166 (58.2)
370 (52.0)
341 (48.0)
1.0 (reference)
1.5 (1.1-2.0)
1.0 (reference)
1.4 (1.0-1.8)
Age
  16-30
  30-40
  40-50
  >50
103 (36.1)
89 (31.2)
59 (20.7)
34 (11.9)
170 (23.9)
202 (28.4)
190 (26.7)
149 (21.0)
2.7 (1.7-4.1)
1.9 (1.2-3.0)
1.4 (0.8-2.2)
1.0 (reference)
2.2 (1.4-3.5)
1.6 (1.0-2.6)
1.0 (0.6-1.7)
1.0 (reference)
Global Assessment of
Functioning (GAF)**
  <35
  35-55
  >=55
79 (39.8)
96 (49.0)
22 (11.2)
109 (26.1)
240 (57.4)
69 (16.5)
2.3 (1.3-4.0)
1.3 (0.7-2.1)
1.0 (reference)
3.4 (1.8-6.3)
2.0 (1.1-3.7)
1.0 (reference)
Type of hospitalisation
  Voluntary
  Involuntary
164 (57.5)
121 (42.5)
620 (87.2)
91 (12.8)
1.0 (reference)
5.0 (3.6-6.9)
1.0 (reference)
4.9 (3.5-6.9)
Psychiatric diagnosis
(DSM-IV)†, ††
  Psychotic disorder
  Depressive disorder
  Anxiety disorder
  Bip. Disorder-manic
  Personality disorder
127 (46.7)
34 (12.5)
15 (5.5)
37 (13.6)
60 (22.1)
271 (39.8)
123 (18.1)
32 (4.7)
58 (8.5)
150 (22.1)
1.3 (1.0-1.7)
0.6 (0.4-1.0)
1.2 (0.6-2.2)
1.7 (1.1-2.6)
1.0 (0.7-1.4)
1.2 (0.9-1.7)
0.7 (0.4-1.1)
1.5 (0.8-3.1)
1.8 (1.1-3.1)
1.2 (0.8-1.8)
*adjusted for gender, age, type of hospitalisation, psychiatric diagnosis.
**n = 615 due to missing values.
†n = 952 due to missing values.
††according to DSM IV, multiple diagnoses could be established.
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Figure 1. A Kaplan-Meier plot of the time from the first day of hospitalisation to seclusion,
comparing patients using and those not using antipsychotics.
The temporal association of antipsychotics with seclusion
We found that among patients with psychotic disorders, 15.3% who used
antipsychotics prior to seclusion during the first week of hospitalisation was
secluded compared to 20.5% of those not using antipsychotics during the first
week. This corresponds with a relative risk of 0.7 (95% confidence interval: 0.5-
1.2).
Figure 2 shows that, in non-psychotic patients, 19 out of 44 (43.2%) started
using antipsychotics during or directly after seclusion compared to 52 out of
288 (18.1%) of non-secluded patients directly after the index date,
corresponding with a relative risk of 2.4 (95% confidence interval: 1.6-3.6).
When looking specifically at patients with psychotic disorders, we also found
that seclusion often preceded the prescription of antipsychotics with a relative
risk of 2.0 (95% confidence interval: 1.2-3.4).
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DISCUSSION
Prevalence of seclusion
The overall prevalence of seclusion found in the current study was high
compared to other European countries [6, 7]; more than a quarter (i.e. 28.6%) of
hospitalised psychiatric patients was secluded at least once during
hospitalisation. This may be related to the Dutch legal situation where
involuntary hospitalisation does not mean that the patient has to accept the
proposed treatment.
Patient-related factors associated with seclusion
Young age, low GAF score and involuntary hospitalisation were significantly
associated with seclusion. It is likely that agitation and aggression are
particularly serious problems in the group of severely ill involuntarily
hospitalised young patients for whom seclusion is needed. We found a
significant association between bipolar disorder (manic episode) and seclusion,
but rather unexpectedly, no clear association between psychotic disorder and
seclusion. This is in contrast with other studies in which it was found that
patients with psychotic disorders showed an increased seclusion rate [1, 8, 9].
Treatment pathways
We found that a delay of seclusion was significantly associated with the use of
antipsychotics. Patients with psychotic disorders who accepted antipsychotics
during the first week of hospitalisation were at a lower risk of seclusion than
patients who did not use these agents, although this difference was not
statistically significant. Our findings are in accordance with the findings of
Hoge et al [10] and Kasper et al [11] who found that patients with psychotic
disorders who refused treatment were significantly more likely to require
seclusion. Our findings are also in line with the studies of Chiles et al [12] and
Chengappa et al [13] who found that treatment with either clozapine or
risperidone was associated with a significant reduction in the use of seclusion.
Apparently, in patients with psychotic disorders, not accepting antipsychotics is
associated with aggression or violence for which seclusion is needed.
Subsequently, in a substantial proportion of patients, antipsychotic treatment
was initiated only during, or directly, after seclusion.
60•  CHAPTER 2.2
Limitations of the study
A limitation of our study is that 38.3% of the GAF scores at admission were
missing in our database. However, patients with available GAF scores did not
differ in gender, age and duration of hospitalisation and only slightly in
diagnostic categories when compared to patients with missing GAF scores. It is
therefore likely that our data are representative for the total population of
patients.
Because of the observational study design, it is possible that confounding
factors influenced the observed associations. Therefore, causal associations
must be carefully interpreted. It is possible that patients not using anti-
psychotics prior to seclusion (probably due to non-compliance) were more
severely ill and therefore more likely to be secluded than patients who used
these agents [10, 11]. However, after adjusting for GAF score, we still found a
significant hazard ratio.
Implications of the study
To our knowledge this is the first time that the temporal relationship between
antipsychotics and seclusion has been studied. There is an ongoing debate on
the application of seclusion in relation to the use of involuntary medication in
the Netherlands. According to the Dutch law, involuntary hospitalisation does
not automatically mean that the patient can be involuntarily treated with
psychotropics (this is in contrast with, for example, the UK). The choice
between coercive measures is left to the treating physician. It should be
primarily focused on the purpose of the measure (i.c. warding off serious
danger) and it should infringe as little as possible on the rights of the patient.
The results of our study suggest that seclusion is generally considered as less
infringing than involuntary medication, but our results also suggest that in the
end (forced) pharmacological treatment remain inevitable for a substantial
proportion of secluded psychotic patients.
Our findings underline the question as to what is preferable for patients who
are aggressive or violent during their stay on an admission ward: seclusion or
treatment with antipsychotics? Antipsychotics are considered essential in both
international and Dutch guidelines for the treatment of patients with psychotic
disorders [14, 15]. Moreover, antipsychotics are also indicated (and registered
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in the Netherlands) for the treatment of severe agitation, including aggression.
Seclusion may have serious physical and psychological adverse effects for the
patient [9, 16]. In addition, during the application of seclusion, staff members
run the risk of getting injured [17, 18]. On the other hand, involuntary
medication may also have considerable (psychological) adverse effects, which,
however, have not been empirically substantiated [19]. No studies on the
effectiveness of seclusion are available [3].
In conclusion, we found that the use of antipsychotics was associated with a
delay of seclusion. Apparently antipsychotics do lead to a reduction of agitation
and aggression both in psychotic and non-psychotic patients. Thus, it is likely
that their use also leads to a lower risk of seclusion. In a substantial proportion
of our patients, antipsychotic treatment was initiated shortly after starting
seclusion. It is likely that in the end (forced) pharmacological treatment is
inevitable for a substantial proportion of secluded psychotic patients. Probably,
earlier (involuntary) use of antipsychotics might have prevented patients from
being secluded. Therefore, we recommend the reconsideration of earlier
(involuntary) application of antipsychotics in agitated and aggressive
(psychotic) patients. Moreover, we recommend more detailed investigations
into the association between antipsychotics and seclusion.
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ABSTRACT
During a 3-months period, determinants of psychotropic drug utilisation
(gender, age, length of stay, reason for admission, disease severity) and data on
psychotropic consumption (type of medication -antidepressants,
benzodiazepines and antipsychotics-, dosage and length of treatment) were
retrospectively collected in a general intensive care unit of a Dutch university
hospital. Daily exposure to psychotropics was standardised in number of
Defined Daily Doses (DDD). Benzodiazepines were used by 35.8% of all patients
(137) during their stay in the ICU whereas 17.5% of all patients used a
neuroleptic agent. Antidepressants were hardly prescribed. High doses of
benzodiazepines (9.9 DDDs)  and low doses of antipsychotics (0.5 DDDs) were
prescribed which probably reflect the outlandish nature of this critically ill
group of patients with the reference group for DDDs. Clear patterns of
determinants of psychotropic drug use in ICU patients were found and both
benzodiazepines, antipsychotics and combined use of these agents could be
associated the determinants assessed. The time patterns we found in terms of
length of stay give clues for further investigations in order to rationalise
psychotropic drug use in the management of severely ill and complex patients.
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INTRODUCTION
Derangement of emotion, cognition and behaviour are frequently encountered
in intensive care settings [1]. The administration of psychotropic drugs is one of
the mainstay strategies to cope with these problems. The use of psychotropic
drugs in our Intensive Care Units (ICUs) was shown to be among the highest in
non-psychiatric departments in this hospital based on a 30% of the total
consumption of neuroleptic agents [2]. Elsewhere, the highest use of parenteral
benzodiazepines was seen in the ICU [3].
Little is known about the determinants of frequent administration of
psychotropic drugs in critical care settings. Indications for sedation during
critical illness commonly centre on patient comfort and acceptance of invasive
treatment, supplemented by analgesics when called for. Drug dosing for
sedation and psychic stability are ideally based on regularly assessed individual
needs and verified according to sedation scores [4]. The often stormy course of
critical illness often complicates such assessment. Moreover, fine tuning drug
dosing of psychotropics in ICU patients is complicated by highly variable
patterns of  drug metabolism and elimination [5].
In order to gain insight in the heavy use of psychotropic drugs we sought to
identify the determinants of prescription in our intensive care by a
retrospective analysis based on daily drug dosages per bed-day.
MATERIALS AND METHODS
Population and data
Data were retrospectively collected over the first three months of 1995 from a
consecutive sample of 137 patients of 18 years or over admitted to two general
ICU’s (17 beds in total). In these units surgical and non-surgical critically ill
adult patients are admitted. Patient data (gender, age, length of stay, reason
for admission, disease severity) and data on psychotropic consumption (type of
medication -antidepressants, benzodiazepines or antipsychotics, dosage and
length of treatment) were extracted from the medical records by means of a
standardised data collection form. The study protocol has been approved by the
Ethics Committee of the University Hospital Nijmegen.
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The Acute Physiologic and Chronic Health Evaluation (APACHE)-II classification
system [6] was used to classify patients according to severity of disease on
admission. This system utilises a score (range 0-71) based on worst values over
24 hours of 12 routine physiologic measurements, age and previous health
status to provide a standardised measure of severity of disease. The height of
the score is correlated with the subsequent risk of hospital death [6]. We
arbitrarily stratified patients according to APACHE-II scores into three groups of
low (0-10), middle (11-20) and high (>21) severity of disease.
Medication was coded according to the WHO Anatomical Therapeutic Chemical
(ATC) coding system. Daily exposure to psychotropics was standardised in
number of Defined Daily Doses (DDD), a standardised technical unit of
measurement defined as the average dose per day for a drug used for its main
indication in adults [7]. Medication termed 'as needed' was not included in the
analysis. If the dose changed during the day, the highest dose was noted.
Analysis
In order to cope with varying lengths of stay in the ICU ‘bed-days’ were taken as
unit of analysis, excluding non 24 hour admission days, effectively omitting the
day of admission and discharge. The odds of psychotropic drug use
(benzodiazepines, antipsychotics or both) per day were calculated comparing
exposed days with non-exposed days. In this way a single patient could
contribute to both exposed and unexposed days. Adjustment for possible
confounding was performed by an unconditional logistic regression analysis.
Data were analysed using EGRET (Epidemiological GRaphics Estimation and
Testing package) [8] and SPSS (Statistical Package for the Social Sciences) [9].
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Table 1. Psychotropic drug use in an ICU, number of patients, number of days one or more drugs
were used, average number of days a drug was used and average daily dose.
Number
of  patients
(n = 137) n(%)
Number
of days
(n = 734) n(%)
Average
number of
days used
Average
daily dose
(DDDs/day)
Any psychotropic
Benzodiazepines
  Midazolam
  Oxazepam
  Diazepam
  Clorazapate
  Clonazepam
Antipsychotics
  Levomepromazine
  Haloperidol
  Alimemazine
  Chlorpromazine
  Trifluoperazine
Antidepressants
  Amitryptiline
58 (42.3)
49 (35.8)
37 (27.0)
14 (10.2)
10 (7.3)
6 (4.4)
2 (1.5)
24 (17.5)
23 (16.8)
5 (3.6)
2 (1.5)
1 (0.7)
1 (0.7)
1 (0.7)
347 (47.3)
255 (34.7)
133 (18.1)
32 (4.4)
13 (1.8)
79 (10.8)
5 (0.7)
196 (26.7)
172 (23.4)
12 (1.6)
18 (2.5)
2 (0.3)
7 (1.0)
1 (0.1)
6.0
5.2
3.6
2.3
1.3
13.2
2.5
8.2
7.5
2.4
9.0
2.0
7.0
1.0
5.9
9.9
13.5
0.2
0.9
9.1
2.1
0.5
0.4
0.7
0.5
0.3
2.0
0.3
RESULTS
The 137 patients accounted for 734 bed-days in the ICU. The mean age of the
patients was 54.1 years ranging from 18 to 83 years. Male patients (59.9%)
outnumbered female patients. The mean APACHE score was 13.6 ranging from
1 to 41. One out of two patients were classified in the medium APACHE group
(score 11-20). We stratified patients according to reason for admission into
surgical ICU admissions and other reasons, mostly severe internal diseases.
Surgical patients had an average stay of 2.7 days in the ICU while non-surgical
patients showed an average stay of 8.0 days.
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A total of 58 patients (42.3%) used one or more psychotropic agents during
their stay in the ICU. These patients had an average stay of 10.7 days and a
median stay of 2.2 days ranging from 1 to 82 days. In contrast, the average ICU
stay for patients without psychotropic drug use was 1.5 days, median 1.0 days,
ranging from 0 to 11 days. Table 1 presents data on the use of individual
psychotropic agents. Benzodiazepines were used by 35.8% of all patients for an
average of 5.2 days. Midazolam was the most commonly prescribed
benzodiazepine, used by 27.0% of all patients and 75.5% of all benzodiazepine
users. Antipsychotics were prescribed to 24 patients (17.5%), with
levomepromazine as the most commonly prescribed neuroleptic, used by 16.8%
of all patients and 96% of all neuroleptic users. Benzodiazepines were
prescribed in high dosages; an average of 9.9 DDDs per day was used by
patients on benzodiazepines. Especially midazolam was prescribed in very high
dosages; an average of 13.5 DDDs, equivalent to 202.5 mg, per day.
Antipsychotics on the other hand were prescribed in low dosages; an average
use of 0.5 DDDs per day. Amitryptiline was the only antidepressant prescribed
and it was used for a short period of one day in a low dosage of 0.3 DDD.
In Table 2, determinants of psychotropic drug use in ICU patients are listed,
further compared according to adjusted odds ratios in Table 3. Benzodiazepines
only were given significantly more to males, the patients aged 45-64 and to the
middle (11-20 ) APACHE score group. Length of ICU stay and reason for
admission were not significantly different for days of benzodiazepine use
compared to days with no psychotropic use. Use of antipsychotics was
significantly associated with males and here also, age 45-64 was significantly
associated with an increased use of psychotropics as well as to the middle
APACHE score group and a longer duration of stay. Admission to the ICU with a
reason other than surgical was seen significantly more often in antipsychotic
users compared to none-users. Combined use of benzodiazepines and
antipsychotics was significantly more often seen in female patients and in age
groups 18-44 and 65 years or over. There was also a strong association with
higher APACHE scores and longer duration of stay in the ICU. Again, admission
to the ICU with a reason other than surgical was associated with combined use
of benzodiazepines and antipsychotics.
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Table 2. Number of days of psychotropic use in ICU patients calculated for different gender, age,
APACHE-II scores, length of stay and reasons for admission.
None Benzodiazepine
only
Antipsychotic
only
Benzodiazepine
and antipsychotic
Total 387 (100%) 151 (100%) 92 (100%) 104 (100%)
Gender
  Female
  Male
205 (53.0)
182 (47.0%)
52 (34.4%)*
99 (65.6%)*
15 (16.3%)*
77 (83.7%)*
82 (78.8%)*
22 (21.2%)*
Age
  18-44
  45-64
  >65
73 (18.9%)
99 (25.6%)
215 (55.6%)
29 (19.2%)*
64 (42.4%)*
58 (38.4%)*
8 (8.7%)*
39 (42.4%)*
45 (48.9%)*
29 (27.9%)*
7 (6.7%)*
68 (65.4%)*
Apache-II score
  0-10
  11-20
  >21
60 (15.5%)
212 (54.8%)
115 (29.7%)
8 (5.3%)*
104 (68.9%)*
39 (25.8%)*
6 (6.5%)*
63 (68.5%)*
23 (25.0%)*
3 (2.9%)*
54 (51.9%)*
47 (45.2%)*
Length of stay
  0-6
  7-13
  14-20
  21-27
  >28
213 (55.0%)
69 (17.8%)
23 (5.9%)
15 (3.9%)
67 (17.3%)
85 (56.3%)
22 (14.6%)
10 (6.6%)
4 (2.6%)
30 (19.9%)
34 (37.0%)*
20 (21.7%)*
15 (16.3%)*
6 (6.5%)*
17 (18.5%)*
29 (27.9%)*
15 (14.4%)*
13 (12.5%)*
14 (13.5%)*
33 (31.7%)*
Reason for admission
  Surgical
  Non-surgical
126 (32.6%)
261 (67.4%)
45 (29.8%)
106 (70.2%)
6  (6.5%) *
86 (93.5%)*
6 (5.8%)*
98 (94.2%)*
*p-value<0.05
In order to adjust for possible confounding, we performed an unconditional
logistic regression analysis including sex, age, APACHE score, number of days in
the ICU and reason for admission in the logistic model (Table 3). Males were
found to be exposed more bed-days to benzodiazepines whereas patients aged
over 65 were less likely to use these agents. Moreover, high APACHE scores
were significantly associated with increased use of benzodiazepines. There was
no association found for benzodiazepine use with length of stay and reason for
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admission. Antipsychotic use was found significantly more in males. Week 2
and 3 of stay at the ICU were strongly associated with a high use of
antipsychotics as well as admission to the ICU for non-surgical reasons.
Combined use of benzodiazepines and antipsychotics was especially seen in the
lowest age groups as well as in patients with a higher APACHE score. Risk on
combined use of benzodiazepines and antipsychotics increased with longer
stay in the ICU with the highest risk in week 4. Again, admission for
non-surgical reasons was associated with a higher combined use.
Table 3. Patient parameters associated with psychotropic drug use. Adjusted odds ratios with 95%
confidence interval (95% CI) are compared in days of psychotropic use compared to days with no
psychotropic drug use. Significant associations are printed in bold.
Benzodiazepines
Only (95% CI)
Antipsychotics
only (95% CI)
Benzodiazepines and
antipsychotics (95% CI)
Gender
  Female
  Male
1.0 (reference)
1.9 (1.2-3.1)
1.0 (reference)
10.7 (4.9-23.2)
1.0 (reference)
0.7 (0.3-1.4)
Age
  18-44
  45-64
  >65
1.0 (reference)
0.8 (0.4-1.5)
0.4 (0.2-0.8)
1.0 (reference)
0.8 (0.3-2.5)
1.2 (0.4-3.3)
1.0 (reference)
0.1 (0.0-0.2)
0.2 (0.1-0.5)
Apache-II score
  0-10
  11-20
  >21
1.0 (reference)
4.7 (2.0-11.4)
4.3 (1.7-10.9)
1.0 (reference)
1.5 (0.5-5.0)
1.0 (0.3-3.6)
1.0 (reference)
11.5 (3.1-42.4)
8.9 (2.3-35.0)
Length of stay
  0-6
  7-13
  14-20
  21-27
  >28
1.0 (reference)
0.7 (0.4-1.3)
0.9 (0.4-2.0)
0.5 (0.2-1.6)
0.9 (0.5-1.6)
1.0 (reference)
2.1 (1.0-4.3)
6.2 (2.4-16.2)
1.6 (0.5-5.4)
1.6 (0.7-3.5)
1.0 (reference)
1.0 (0.5-2.1)
3.2 (1.3-8.1)
5.2 (2.0-13.4)
2.2 (1.1-4.5)
Reason for  admission
  Surgical
  Non-surgical
1.0 (reference)
1.5 (0.9-2.6)
1.0 (reference)
19.5 (7.1-53.9)
1.0 (reference)
8.9 (3.2-24.7)
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DISCUSSION
In this hospital’s ICU’s patterns of psychotropic drug use were distinguished
against a background of fairly heavy use of benzodiazepines and a considerable
use of neuroleptics. The high use of midazolam is in agreement with results of
other studies [10-13]. Our findings of the use of benzodiazepines, prescribed to
35.8% of all patients and antipsychotics, prescribed to 17.5%, differ from
currently available information on the use of psychotropic agents in critically ill
patients. An increase in the use of benzodiazepines in a surgical ICU from 26%
to 57% was prescribed between two periods in 1986-1987 and 1989-'90,
whereas the use of antipsychotics, specifically haloperidol, remained constant
about 10% [13].  In another study benzodiazepines were prescribed in 43% of
the patients in a surgical ICU [10]. The antipsychotic haloperidol was prescribed
in 8.1% and droperidol in 0.4%. In a recent multi-center study drug admini-
stration data were collected for five days in 74 ICUs [14]. Of 1222 patients
about 55% used benzodiazepines; neuroleptics were administered in circa 7%.
It is likely that the patterns of psychotropic drug use differ amongst ICU’s,
based on differences in patient populations and local drug preferences.
However our benzodiazepine use compared to these studies was low and
neuroleptic use high. This could also be explained by the fact that in our study
the phenothiazine levomepromazine was found to be used whereas in other
studies benzodiazepines were used. This is interesting because phenothiazines
may be used to potentiate the analgesic and sedative effects of analgetics but
with the exception of anti-emetic effects they offer no substantial advantage
over the more commonly used benzodiazepine-narcotic combination [15]. No
comparison was made in our study to assess pain treatment.
Our data showed a very low antidepressant use. This probably represents the
difficulty of making the diagnosis in this clinical setting [16], although
depression is thought to occur with high frequency in the ICU patient
population [17, 18].
This study revealed that high -in terms of DDDs- doses of benzodiazepines and
low doses of antipsychotics were prescribed. These observations of unusual
DDDs probably reflect the outlandish nature of this critically ill group of
patients with the reference group for DDDs. The DDD as a unit of measurement
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was primarily developed for ambulatory care settings, where much lower
dosages of benzodiazepines and higher dosages of antipsychotics are
customary. In the absence of widely accepted ICU sedation goals and means the
introduction of the DDD as unit of analysis here may be seen as inappropriate.
However, it helps to focus on a need to arrive at such standards. Reaching
consensus will be a challenge in view of yet better defined and widely accepted
assessment scores and the highly variable pharmacokinetics in ICU patients.
Our finding that patients were exposed to relatively small amounts of
antipsychotics is in agreement with the results of Zitman et al. They found by
interviewing senior consultants of the non-psychiatric departments that
standard doses prescribed were well below the DDD [2]. Because the DDD was
not used as a unit of comparison in other studies on the psychotropic use in
ICUs it is not possible to compare our data to those of other studies.
In this study we found that benzodiazepine prescriptions are not as strongly
associated with patient characteristics as is the use of antipsychotics only or
combined with benzodiazepines. It is likely that benzodiazepines are primarily
prescribed to attain a basic level of sedation. It is not known why there is a
strong association between male sex and antipsychotic drug prescription.
Physicians are probably more likely to prescribe a combination of
benzodiazepines and antipsychotics because young patients have shorter
elimination times for many agents compared to geriatric patients. However,
this is not true for the frequently prescribed short half-life benzodiazepines
such as midazolam which may not be an increased risk for the elderly [1]. High
risk on the use of antipsychotics only or combined with benzodiazepines can be
explained by the fact that a long stay in the ICU, high APACHE scores and an
admission for non surgical reasons probably indicates severely ill patients who
are likely to suffer from a delirium. Although no ideal sedative exists for this
disorder haloperidol has been most often recommended for agitated, restless
and frightened patients [1,19]. Some authors used this agent combined with a
benzodiazepine when repeated doses of haloperidol failed to give a therapeutic
response [1]. This combination may produce fewer extrapyramidal side effects
[1]. An other explanation for the association of a long stay in the ICU with
mainly combined use of benzodiazepines and antipsychotics is that the use of
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these drugs prolongs stay in the ICU because of excessive sedation with
cognitive impairment. In case of the first explanation it is conceivable that
these drugs are under-utilised whereas in case of the second explanation these
drugs are probably over-utilised. Because diagnostic data were not collected in
this study, it was not clear whether the use of these drugs was appropriate or
inappropriate.
The utilisation data of this study imply that side effects of benzodiazepines and
antipsychotics must occur fairly regularly in the ICU. This stresses the need to
search for these effects, even while they may be difficult to discern from other
symptoms in obtunded, critically ill patients [2].
In conclusion, we found clear patterns of determinants of psychotropic drug
use in ICU patients. Both benzodiazepines, antipsychotics and combined use of
these agents could be associated with gender, age, disease severity, length of
stay and reasons for admission. The time patterns we found in terms of length
of stay give clues for further investigations in order to rationalise psychotropic
drug use in the management of severely ill and complex patients. A limitation
of this study was the fact that only complete days of use were included and
that drugs prescribed 'as needed' were not included in the analysis. Therefore,
the actual use was certainly higher than described here. Consequently, we
recommend more detailed investigations of the prescription practice of
psychotropics in the ICU with the collection of diagnostic data.
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ABSTRACT
In a previously published study (Chapter 3.1), we sought to identify
determinants of psychotropic drug use in a retrospective case-control design.
Therefore possible determinants of psychotropic drug use (gender, age, length
of stay, reason for admission, disease severity) and psychotropic agents used
(antidepressants, benzodiazepines, antipsychotics or benzodiapines and anti-
psychotics concomitantly used) were retrospectively collected. Bed-days were
used as unit of analysis and no corrections were made for correlated measures.
The objective of the present study is to compare two different study designs to
identify possible determinants of psychotropic drug use in an ICU. In a logistic
regression analysis, odds rates were calculated for exposed days to
psychotropics compared with non-exposed days. In order to adjust for
correlated measures, or cluster effects through repeated measures in individual
patients, logistic regression with a random effects model was performed. We
found that adjustment for correlated measures did not result in major changes
in the odds ratios. However, we did find that with more observations per
cluster, adjustment for correlation has greater effect.
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INTRODUCTION
In an earlier published study, we sought to identify determinants of
psychotropic drug prescription in a retrospective case-control design [1]. In
former studies it was concluded that the use of psychotropics in intensive care
units (ICUs) is high compared to other non-psychiatric departments in a general
hospital [2, 3]. In our previous study we found clear patterns of determinants of
psychotropic drug use in ICU patients and both benzodiazepines, antipsychotics
and combined use of these agents were associated with gender, age, disease
severity, reason for admission and length of stay [1].
In order to cope with varying lengths of stay, we used bed-days as unit of
analysis. Patients who used psychotropic drugs (cases) acted as their own
controls because days exposed to psychotropics were compared to non-
exposed days [1]. However, in this analysis no corrections were made for the
fact that the observations were correlated.
The objective of the present study is to compare two different study designs to
identify possible determinants of psychotropic drug use in an ICU. We will
discuss the methodological considerations and pitfalls concerned with these
methods.
MATERIAL AND METHODS
Study population and data
We retrospectively collected data over the first three months of 1995 from a
consecutive sample of 137 patients of 18 years or over admitted to two general
ICUs (17 beds in total) in the Netherlands with post-surgical and non-surgical
severely ill patients. Patient data (gender, age, length of stay, disease severity,
drug use during previous day and reason for admission) and psychotropics used
(antidepressants, benzodiazepines, antipsychotics or benzodiazepines and
antipsychotics concomitantly used) were extracted from the medical records by
means of a standardised data collection form. Medication was coded according
to the WHO Anatomical Therapeutic Chemical (ATC) coding system. Medication
termed ‘as needed’ was not included in the analysis.
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The Acute Physiologic and Chronic Health Evaluation (APACHE)-II classification
system was used to classify patients according to severity of disease on
admission [4]. This system uses a score (range 0-71) based on worst values
during 24 hours of 12 routine physiologic measurements combined with age
and previous health status to provide a standardised measure of severity of
disease. This score has been validated and is correlated with subsequent risk on
hospital death [4]. Patients were stratified according to APACHE-II scores into
three categories: low (0-10), middle (11-20) and high (>21) severity of disease.
Furthermore, patients were stratified according to reason for admission into:
surgical ICU admission and other reasons, mostly severe internal diseases.
Population and data have extensively been described before [1]. In addition, the
variable ‘drug use during previous day’ was added which included drugs used
during the day before the day under observation.
Study designs
Bed-days were taken as unit of analysis in order to cope with varying lengths of
stay in the ICU. Non-24 hour admission days were excluded, effectively
omitting the day of admission and discharge.
1) In a logistic regression analysis, we compared exposed days to psychotropics
with non-exposed days and calculated odds ratios for various possible factors
associated with exposed days. In this way, a single patient could contribute to
both exposed and unexposed days. Adjustment for possible confounding was
performed with exposed days as dependent variables and all possible factors
associated with exposed days as independent variables.
2) In order to adjust for correlated measures, or cluster effects through the
repeated measures in individual patients, we performed logistic regression
with a random effects model. Again, exposed days were compared with non-
exposed days, but here the patient-identifier was included as a random effect
term. A logistic-binomial model was used to adjust for correlated measures and
possible confounders. Data were analysed using EGRET and SPSS package.
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Table 1. Basic characteristics of ICU patients (N = 137).
Number of patients
n (%)
Gender
  Female
  Male
Age
  18-44
  45-64
  >65
APACHE-II score
  0-10
  11-20
  >21
  missing value
Length of stay
  0-6
  7-13
  14-20
  21-27
  >28
Reason for admission
  Surgical
  Non-surgical
Psychotropic drugs
  Benzodiazepines
  Antipsychotics
  Antidepressants
55 (40.1)
82 (59.9)
46 (33.6)
40 (29.2)
51 (37.2)
42 (30.7)
73 (53.3)
20 (14.6)
2 (1.5)
111 (81.0)
14 (10.2)
4 (2.9)
3 (2.2)
5 (3.6)
68 (49.6)
69 (50.4)
49 (35.8)
24 (17.5)
1 (0.7)
RESULTS
In Table 1 basic characteristics are shown. Mean age of the 137 patients was
54.1 years (range: 18-83 years). More male patients (59.9%) than female
patients were admitted to the ICU. Mean APACHE score was 13.6 (median 13;
range: 1-41) Mean length of stay of all patients was 5.4 days (median: 1 day;
range: 0-82 days). The number of patients admitted for non-surgical reasons,
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69 (50.4%), was equal to the number of patients admitted for surgical reasons.
These non-surgical patients had the longest length of stay with a mean
duration of 8.0 days (median: 2; range: 0-82) compared to surgical patients who
had a mean length of stay of 2.7 days (median: 1; range: 1-23). We found that
49 patients (35.8%) used a benzodiazepine and 24 (17.5%) used an
antipsychotic anytime during hospitalisation.
Table 2. Patient parameters associated with psychotropic drug use. Adjusted odds ratios with 95%
confidence interval are compared in days of psychotropic use compared to days with no
psychotropic drug use. Significant associations are printed in bold.
Benzodiazepines
only
Antipsychotics
only
Benzodiazepines
& antipsychotics
Gender
  Female
  Male
1.0 (reference)
1.7 (1.0-3.0)
1.0 (reference)
5.2 (2.2-12.4)
1.0 (reference)
0.8 (0.3-2.5)
Age
  18-44
  45-64
  >65
1.0 (reference)
0.9 (0.4-2.0)
0.7 (0.4-1.4)
1.0 (reference)
1.1 (0.3-3.9)
1.0 (0.3-3.1)
1.0 (reference)
0.3 (0.1-1.2)
0.4 (0.1-1.5)
Apache-II score
  0-10
  11-20
  >21
1.0 (reference)
2.6 (1.0-6.8)
2.7 (1.0-7.5)
1.0 (reference)
0.9 (0.3-3.1)
0.5 (0.1-2.1)
1.0 (reference)
1.8 (0.3-8.7)
1.8 (0.3-11.4)
Length of stay
  0-6
  7-13
  14-20
  21-27
  >28
1.0 (reference)
0.7 (0.4-1.4)
0.8 (0.3-2.1)
0.4 (0.1-1.5)
0.8 (0.4-1.5)
1.0 (reference)
1.7 (0.7-4.3)
4.5 (1.2-17.4)
0.8 (0.2-4.0)
1.2 (0.4-3.1)
1.0 (reference)
1.2 (0.3-4.5)
4.4 (0.8-23.5)
1.8 (0.3-11.1)
1.1 (0.3-4.0)
Drug use during previous day
  Benzodiazepine
  Antipsychotic
11.8 (7.3-19.2)
0.5 (0.1-1.4)
2.2 (0.9-5.8)
23.2 (11.6-46.4)
21.0 (8.1-54.4)
29.7 (11.6-76.3)
Reason for admission
  Surgical
  Non-surgical
1.0 (reference)
1.4 (0.8-2.6)
1.0 (reference)
6.6 (2.1-20.1)
1.0 (reference)
1.7 (0.4-7.0)
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Table 2 shows adjusted odds ratios for patient parameters related to the
number of days that benzodiazepines, antipsychotics or both were used. The
137 patients accounted for 734 bed-days. Male gender and APACHE-II score
over 10 were significantly associated with the use of benzodiazepines. The use
of antipsychotics was significantly more found in men, longer length of stay
and a non-surgical reason for admission. Furthermore, using a benzodiazepine
or antipsychotic during previous day was strongly associated with use of the
same type of psychotropic or combined use of these drugs on the following day.
Although not significant, previous benzodiazepine use was associated with
higher risk on subsequent antipsychotic use and antipsychotic use with lower
risk on subsequent benzodiazepine use with odds ratios of 2.2 (95% confidence
interval: 0.9-5.8) and 0.5 (95% confidence interval (0.1-1.4).
Table 3 shows patient parameters related to the number of days that benzo-
diazepines, antipsychotics or both were used, adjusted for possible con-
founding and in addition to Table 2 also for correlated measures. No major
differences in the point-estimates of the odds ratios were found. However,
confidence intervals were wider in most cases and less significant values were
found.
In Figure 1 the effect of increasing number of observations per cluster on the
logistic binomial model is illustrated with two examples. Figure 1a shows the
effect on the odds ratio for use of antipsychotic drugs during the previous day
on antipsychotic prescribing, while Figure 1b shows the same effect on the
odds ratio for non-surgical admissions. Both graphs show an increased
diverging with more measurements per cluster indicating a greater effect of
adjusting for correlation with more observations.
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Table 3. Days of psychotropic use compared to days with no use of psychotropics (presented
as odds ratios with 95% confidence interval) adjusted for possible confounding and
correlated measures in a logistic binomial model for distinguishable data with random
effects. Significant associations are printed in bold.
Benzodiazepines
only
Antipsychotics
only
Benzodiazepines
& antipsychotics
Gender
  Female
  Male
1.0 (reference)
1.5 (0.8-2.9)
1.0 (reference)
4.7 (1.6-14.0)
1.0 (reference)
1.7 (0.2-12.6)
Age
  18-44
  45-64
  >65
1.0 (reference)
0.8 (0.3-2.1)
0.8 (0.3-1.7)
1.0 (reference)
1.0 (0.2-4.6)
0.9 (0.2-3.5)
1.0 (reference)
0.2 (0.0-2.8)
0.3 (0.0-2.9)
Apache-II score
  0-10
  11-20
  >21
1.0 (reference)
2.4 (0.8-6.8)
3.5 (1.1-11.0)
1.0 (reference)
0.9 (0.2-3.6)
0.5 (0.1-2.6)
1.0 (reference)
2.0 (0.1-29.2)
1.0 (0.0-19.9)
Length of stay
  0-6
  7-13
  14-20
  21-27
  >28
1.0 (reference)
0.6 (0.3-1.2)
0.6 (0.2-1.9)
0.2 (0.0-1.2)
0.5 (0.2-1.2)
1.0 (reference)
1.7 (0.6-4.5)
5.8 (1.0-34.5)
0.8 (0.1-4.8)
1.8 (0.4-7.8)
1.0 (reference)
1.5 (0.3-8.4)
5.6 (0.5-58.5)
4.9 (0.2-109.8)
1.0 (0.2-7.2)
Drug use during previous day
  Benzodiazepine
  Antipsychotic
9.9 (5.8-16.8)
0.5 (0.1-1.5)
2.5 (0.9-7.0)
18.5 (7.6-45.0)
23.1 (5.2-102.7)
9.3 (1.8-48.9)
Reason for admission
  Surgical
  Non-surgical
1.0 (reference)
1.3 (0.6-2.5)
1.0 (reference)
5.3 (1.4-20.0)
1.0 (reference)
2.2 (0.3-17.5)
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Figure 1. Effects of increasing number of observations per cluster on the logistic binomial
model.
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DISCUSSION
The term ‘repeated measures’ refers to multiple observations of either
exposure or outcome on the same sampling unit, often a patient or subject [5].
Often these observations within the same subject will be correlated and this
has to be taken into account when analysing these data. However in
pharmacoepidemiological studies, possible intra-subject correlation is often not
taken into account. With more and more longitudinal databases available for
observational research, the progress in measurement of exposure patterns over
time, and the availability of outcomes measures on detailed patient level, the
number of studies involving repeated measures is increasing.
In a study we performed on determinants of psychotropic drug use in patients
admitted to an intensive care unit in a general hospital we had data available
on the drug exposure for each day during admission as well as data on a
patient-level [1]. We considered each patient-day as an independent
observation and subsequently looked at days with psychotropic drug use
(cases) and compared them to days without psychotropic drug use (controls) in
a logistic regression model. In the present study, we took the correlation that is
to be expected between the repeated measures within the same patient into
account and compared the two methods. We found no major differences in the
point estimators of the odds ratios between the two methodologies used.
However, the confidence intervals after adjustment for correlated measures
were considerably wider in most cases resulting in a loss of statistical
significance. It is to be expected that adjustment for correlated measures has a
bigger effect when more observations per cluster are present. We simulated
this in our data by stratifying for length of follow-up, or in other words number
of patient-days contributed to the dataset. We saw an increase in the effect of
adjustment for correlation with increasing number of observations per patient
included in the model. Adjustment for correlation seems to be especially
pertinent with multiple observations per subject.
In the present study, in addition to the above mentioned methodological
considerations and in addition to the former study [1], we found that previous
benzodiazepine and antipsychotic use were significantly associated with
psychotropic use during the following day. Apparently critically ill patients
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admitted on the intensive care setting need psychotropics for longer periods of
time. Although not significant, the association of previous benzodiazepine use
with higher risk on antipsychotic use the following day and the association of
previous antipsychotic use with lower risk on benzodiazepine use the following
day suggests that during critical illness in patients who need sedation,
physicians consider benzodiazepines as first choice and the use of
antipsychotics or combined use of benzodiazepines and antipsychotics as
second. It is likely that benzodiazepines are used for a basic level of sedation. In
the ICU, many risk factors in the patient and pharmacological and
environmental risk factors of delirium are seen [6]. After a few days in this
setting patients may develop a delirium [7]. Antipsychotics are the cornerstone
in its treatment [6].
In conclusion, we have shown that adjustment for correlated measures in data
with many observations per patient is feasible and relatively simple to perform.
Although in this study, adjustment did not result in major changes in the odds
ratios found, we did find that with more observations per cluster, adjustment
for correlation has greater effect.
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ABSTRACT
Little is known about psychiatric and behavioural factors associated with
psychotropic drug use in settings for people with intellectual disabilities. The
aim of this study was to measure the point prevalence of psychotropic drug use
in a problem behaviour group (PBG) consisting of intellectually disabled
residents of group homes compared to a random group (RG) and to gain insight
in possible factors that are associated with group membership. From all group
homes in the Netherlands, 573 problematic residents were selected by staff
(one resident from each home) and 1479 residents were randomly sampled
from all the homes. Mental health problems were measured using the Reiss
Screen for Maladaptive Behavior and the Psychopathology Instrument for
Mentally Retarded Adults. Psychotropics (excluding anticonvulsants) were used
by 52.6% of the PBG and by 22.8% of the RG. Young age, psychotic, anxiety and
aggression symptoms were significantly associated with the PBG as was the
use of antipsychotics and antidepressants. A low prevalence of antidepressants
or mood stabilisers, antipsychotics and anxiolytics was found in residents with
affective, psychotic, or anxiety symptoms. It is likely that the group home staff
finds it difficult to deal with socially disruptive behaviour. Our findings suggest
that a considerable number of residents with psychiatric or behavioural
symptoms are undertreated.
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INTRODUCTION
Although studies on mental health problems among people with intellectual
disabilities vary greatly in sampling and identification techniques [1] there is a
consensus that people with intellectual disabilities are at higher risk of mental
health problems than people from the general population [1-5].
Because of complicated behavioural problems in this population, psychotropic
drug therapy is often attempted, but is suspected to interfere with cognitive
and behavioural skills [6]. Nevertheless, prevalence rates of psychotropic and/or
anticonvulsant drug use among persons with intellectual disabilities are high,
ranging from 44 to 60% in institutional populations and from 35 to 45% in
community settings [7]. According to a recent Dutch survey, psychotropic
agents including anticonvulsants were prescribed to 41% of an institutionalised
population and to 29% of group home residents. Overall, antipsychotic agents
were prescribed to 17.5%, anxiolytics to 6.8%, antidepressants to 3.6% and
anticonvulsants to 18.4% of the total sample [8].
Little is known about psychiatric and behavioural factors associated with the
prescription of psychotropic drugs and how appropriately these drugs are
prescribed in settings for people with intellectual disabilities [9]. Examining the
relation between psychiatric diagnosis and medication regime in a group of
242 institutionalised people with intellectual disabilities and psychiatric
disorders, 55% of the diagnosis-medication combinations were found to be
either uncertain or probably inappropriate [10]. According to a more recently
published review, many people receiving psychotropic agents had no
psychiatric diagnosis in their case files and medication was sometimes
prescribed without any specific target symptom or diagnosis [11].
The present study was designed to measure the point prevalence of
psychotropic drug use in intellectually disabled group home residents with
problem behaviour. Furthermore, we wanted to gain insight into this group of
residents by analysing the possible factors associated with the problem
behaviour group.
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MATERIALS AND METHODS
Setting
In the Netherlands, the term ‘group home’ refers to a multitude of community-
based settings, ranging from houses with over 20 residents (living in three to
four units) to annexes of these houses where fewer persons reside, sometimes
only two or three. In contrast to the larger group home, the employees are not
continuously present in the annexes. If possible, residents of group homes
make use of general health care facilities. All group home residents have mild
or moderate intellectual disabilities. In total, there are 573 group homes in the
Netherlands that house 15,622 persons with intellectual disabilities
Subjects
The staff in each group home was instructed to select one resident they
considered as having the most severe behavioural problems for the problem
behaviour group (PBG). A random group (RG) of 1479 residents with intellectual
disabilities was drawn up by selecting every ninth resident from a random list
in each group home [12]. As a consequence of this method, larger group homes
provided more residents for the RG.
Procedure
Information on residents was collected in 1996 using a questionnaire to be
completed by the staff. The questionnaire included the following topics:
gender, age, previous mental health care and somatic disorder or handicap.
Mental health problems were measured with the Dutch versions of the Reiss
Screen for Maladaptive Behavior and the Psychopathology Instrument for
Mentally Retarded Adults (PIMRA). Information on the current use of
psychotropic drugs were recorded in terms of type and daily dosage.
Psychotropic agents
Psychotropic drugs were mainly prescribed by general practitioners.
Psychotropic use was coded according to the WHO Anatomical Therapeutic
Chemical (ATC) coding system. Actual daily exposure to psychotropics
(antipsychotics, anticholinergics, antidepressants, anxiolytics, hypnotics /
sedatives, antihistamines -promethazine- and anticonvulsants) was converted
into the number of Defined Daily Dosages (DDD-equivalents), a standardised
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technical unit of measurement, defined as the average dose per day for a drug
used for its main indication in adults [13].
Instruments
The Dutch versions of the Reiss Screen for Maladaptive Behavior [14] and the
Psychopathology Instrument for Mentally Retarded Adults (PIMRA) [15] were
used for measuring mental health problems.
The Reiss Screen for Maladaptive Behavior
The Reiss Screen for Maladaptive Behavior is a questionnaire for informants
developed to assess the risk of mental health problems among persons with
mental retardation [16]. It consists of 35 items describing problem behaviour
resulting in a total score indicative of general mental health. The Reiss Screen
has eight subscales: psychosis, aggression, autism, paranoia, depression
behavioural signs, depression physical signs, dependent disorder and avoidant
personality disorder, each resulting in a subscale score. The Dutch version has
good internal consistency for the total score with a Cronbach’s alpha of .90 and
moderate reliability for most subscales, ranging from .50 (autism) to .85
(aggression) [17].
Psychopathology Instrument for Mentally Retarded Adults
This instrument is based on DSM-III-R and consists of 56 items in eight
subscales: schizophrenia, affective disorders, psychosexual disorders,
adaptation disorders, anxiety disorders, somatoform disorders, personality
disorders and inadequate (social) adaptation (not a DSM-III-R classification)
[18]. Two versions were developed: a self report version and an informant
version, which was used in this study. All PIMRA subscales consist of seven
items (symptoms), four of which must be present for the disorder to be
diagnosed [18]. The Dutch version of the PIMRA has good internal consistency
for the total score (.90) with subscale reliabilities ranging from .46 (personality
disorder) to .81 (somatoform disorder) [19].
Behavioural and psychiatric symptoms
To gain insight into intellectually disabled group home residents with problem
behaviour, four groups of symptoms were selected: affective, psychotic, anxiety
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and aggression symptoms. Because there are no conclusive studies regarding
the validity of the subscales of the Reiss Screen and the PIMRA, scale scores
must be interpreted with caution. On basis of these instruments, we could not
establish a diagnosis in terms of DSM-IV or ICD-10. Additionally, drugs are often
prescribed for target symptoms in this population, not for disorders. Therefore,
we will present the mental health problems in terms of symptoms.
In the Results section, residents were considered to have affective symptoms
when they were positive for two of the three depression subscales (behavioural
and physical signs for depression according to the Reiss Screen and affective
disorder according to the PIMRA). Residents positive for two of the three
psychosis subscales (psychosis and paranoia according to the Reiss Screen and
schizophrenia according to the PIMRA) were considered as people with
psychotic symptoms. Residents had aggressive symptoms if they scored above
the cut-off in the similar Reiss Screen subscale. Where residents scored above
the cut-off in the anxiety disorder subscale of the PIMRA, they were considered
as having symptoms.
Analysis
Using logistic regression analysis, we compared the PBG with the RG and
calculated prevalent odds ratios for various possible factors associated with the
PBG including gender, age, affective, psychotic, anxiety and aggression
symptoms and psychotropic drug use. Adjustment for possible confounding
was performed with the PBG as dependent variable and all possible factors
associated with the PBG as independent variables.
We used the Statistical Package for the Social Science [20] to analyse the data.
RESULTS
The response rate for the PBG was 68.9% (395 returned questionnaires) and
71.7% (1.061 returned questionnaires) for the RG. The mean age of residents in
the PBG was 39 years (SD: 11.8) and this was 42 years (SD: 13.4) in the RG. The
prevalence of people with Down’s syndrome was 6.1% in the PBG and 14.8% in
the RG. In the PBG, 8.2% had experienced seizures in the past and a similar
percentage of 7.3% was identified in the RG. 70.4% of the PBG had previous
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contact with the mental health services, the figure being 18.5% for the RG.
Anxiety and aggression symptoms were most prevalent in the PBG. Of these
residents, 52.9% and 43.1% suffered from these symptoms, compared to 22.0%
and 4.9% in the RG. 39.2% of the PBG suffered from more than one type of
symptom in contrast to 7.0% in the RG
Table 1. Gender, age, psychiatric-/behavioural symptoms and psychotropic agents associated
with the problem behaviour group (PBG) (n = 395*) compared to the random group (RG) (n =
1061*). Crude odds ratios and adjusted odds ratios calculated with 95% confidence interval
(95% CI). Significant associations are printed in bold.
PBG
n (%)
RG
n (%)
Crude odds ratio
(95% CI)
Adjusted odds
ratio (95% CI)
Male 213 (54.1) 521 (49.3) 0.8 (0.7-1.0) 0.8 (0.6-1.1)
Age group (years)
  18-35
  36-50
  51-65
  >=66
172 (44.7)
149 (38.7)
58 (15.1)
6 (1.6)
337 (32.2)
437 (41.7)
207 (19.8)
67 (6.4)
1.0 (reference)
0.7 (0.5-0.9)
0.6 (0.4-0.8)
0.2 (0.1-0.4)
1.0 (reference)
0.8 (0.5-1.1)
0.5 (0.3-0.7)
0.3 (0.1-0.7)
Psychiatric/behavioural
symptoms**
  Affective symptoms
  Psychotic symptoms
  Anxiety symptoms
  Aggression symptoms
98 (26.3)
80 (21.3)
202 (52.9)
163 (43.1)
64 (6.4)
22 (2.2)
224 (22.0)
50 (4.9)
5.2 (3.7-7.4)
12.1 (7.3-20.4)
4.0 (3.1-5.1)
14.6 (10.2-21.1)
1.2 (0.7-2.1)
2.6 (1.4-5.0)
1.9 (1.4-2.7)
10.0 (6.6-15.2)
Psychotropic drugs
  Antipsychotic
  Antidepressant
  Anxiolytic
  Anticonvulsant
159 (41.2)
59 (15.3)
60 (15.5)
83 (21.5)
175 (16.7)
48 (4.6)
65 (6.2)
167 (15.9)
3.5 (2.7-4.6)
3.8 (2.5-5.7)
2.8 (1.9-4.1)
1.4 (1.1-2.0)
2.1 (1.4-3.1)
2.4 (1.5-3.7)
1.3 (0.8-1.9)
0.9 (0.7-1.2)
* In most analyses the n was slightly smaller due to missing values.
** Psychiatric/behavioural symptoms: 1) Affective symptoms: positive for 2 of 3 depression
subscales (depression behavioural signs and depression physical signs of the Reiss Screen and
affective disorder of the PIMRA). 2) Psychotic symptoms: positive for 2 of 3 psychosis
subscales (psychosis and paranoia of the Reiss Screen and schizophrenia of the PIMRA).  3)
Anxiety symptoms: positive for the anxiety disorder subscale of the PIMRA. 4) Aggression
symptoms: positive for the aggression subscale of the Reiss Screen.
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Table 1 reveals the prevalence rates of patient characteristics and the
associations between these characteristics and group membership (PBG or RG).
Pipamperone, a serotonine-2/dopamine-2 antagonist and thioridazine, were
the most frequently used antipsychotic drugs in both groups. In the PBG,
pipamperone was prescribed to 31.4% of antipsychotic users and to 20.9% of all
psychotropic users and thioridazine to 17.6% and 11.7%. In the RG,
pipamperone was used by 17.7% of antipsychotic users and by 8.9% of all
psychotropic users, thioridazine by 14.9% and 7.4%, respectively. Young age,
psychotic symptoms, anxiety symptoms and aggression symptoms were found
to be significantly associated with the PBG. Antipsychotics and antidepressants
were significantly more prescribed in the PBG.
Table 2. Prevalence of psychotropic drug use in the PBG (n = 395*) and the RG (n = 1061*).
PBG
n (%)
RG
n (%)
Psychotropic drugs
  Including anticonvulsants
  Excluding anticonvulsants
239 (61.8)
203 (52.6)
349 (33.2)**
240 (22.8)**
Number of drugs used
  1
  2
  3
  >=4
107 (27.7)
65 (16.8)
43 (11.1)
24 (6.2)
170 (16.2)**
102 (9.7)**
59 (5.6)**
18 (1.7)**
Number of drug categories used
  1
  2
  3
  >=4
123 (31.9)
73 (18.9)
32 (8.3)
11 (2.8)
223 (21.3)**
97 (9.2)**
28 (2.7)**
1 (0.1)**
* In most analyses the n was slightly smaller due to missing values.
**p-value <0.05 PBG compared to the RG.
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Table 2 shows prevalence rates of psychotropic drug use. In the PBG, 61.8% of
the residents used a psychotropic agent, in contrast to 33.2% in the RG. These
prevalence rates were 52.6% and 22.8% with anticonvulsants left out. The
prevalence of residents using three or more drugs in the PBG was 17.3%,
whereas 7.3% of the RG used three or more drugs. People using psychotropic
drugs of three or more drug categories (antipsychotics, anticholinergics,
antidepressants, anxiolytics, hypnotics/sedatives, antihystamines and
anticonvulsants) of the PBG (11.1%) outnumbered people of the RG using drugs
of three or more drug categories (2.8%).
The lowest dosages were found in the antipsychotic group with a mean dosage
of levomepromazine of 0.2 DDD (SD: 0.1) in the PBG and 0.1 DDD (SD: 0.1) in
the RG. More potent antipsychotics were used in higher dosages. For example,
the mean dosage of haloperidol in the PBG was 0.7 DDD (SD: 0.6) and 0.6 DDD
(SD: 0.6) in the RG.
Table 3. Number of residents using a psychotropic drug calculated for different symptom
clusters in the PBG (n = 395) and the RG (n = 1061). Mental health problems were measured by
using Dutch versions of the Reiss Screen for maladaptive behavior and the PIMRA.
Affective symptoms*
n (%)
Psychotic symptoms**
n (%)
Anxiety symptoms†
n (%)
PBG
n = 98
RG
n = 64
PBG
n = 80
RG
n = 22
PBG
n = 202
RG
n = 224
Antidepressants
Antipsychotics
Anxiolytics
Hypnotics/sedatives
Anticonvulsants
28 (28.6)
58 (59.2)
26 (26.5)
11 (11.2)
20 (20.4)
10 (15.6)
26 (40.6)
13 (20.3)
1 (1.6)
10 (15.6)
17 (21.3)
42 (52.5)
18 (22.5)
7 (8.8)
21 (26.3)
3 (13.6)
10 (45.5)
2 (9.1)
0 (0)
4 (18.2)
41 (20.3)
107 (53.0)
43 (21.3)
12 (5.9)
41 (20.3)
19 (8.5)
69 (30.8)
24 (10.7)
3 (1.3)
41 (18.3)
*Positive for 2 of 3 depression subscales (depression behavioural signs and depression physical
signs of the Reiss Screen and affective disorder of the PIMRA).
**Positive for 2 of 3 psychosis subscales (psychosis and paranoia of the Reiss Screen and
schizophrenia of the PIMRA).
†Positive for the anxiety disorder subscale of the PIMRA.
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In order to gain more insight into the use of medication, prevalence rates of
drugs calculated for affective, psychotic and anxiety symptoms are shown in
Table 3. Antipsychotics were the most frequently prescribed agents in both
groups. In the PBG, 28.6% of the patients with affective symptoms used
antidepressants. In the RG, 15.6% of the patients with affective symptoms used
these drugs. Antipsychotics were prescribed in 52.5% of the patients with
psychotic symptoms in the PBG, compared to 45.5% of the patients in the RG.
Residents with anxiety symptoms from the PBG more often used anxiolytics
(21.3%) than residents from the RG with anxiety symptoms (10.7%).
DISCUSSION
The present study involving 1456 intellectually disabled group home residents
showed, as expected, that psychotropic drug use was much higher in
problematic group home residents than in the random study group. We
hypothesise that the administration of psychotropic drugs, especially
antipsychotics, is often the result of difficulties in dealing with problematic
residents. Furthermore, it is likely that considerable numbers of residents with
psychiatric or behavioural symptoms are undertreated.
We found that 61.8% of the PBG compared to 33.2% of the RG used at least one
psychotropic agent including anticonvulsants and 52.6% compared to 22.8%
excluding anticonvulsants. This high use in the PBG is consistent with the
findings of Jacobson [21], who found an even higher prevalence rate (70.8%) of
psychotropic drug use (excluding anticonvulsants) in residents with psychiatric
disorders living in community care facilities. High prevalence rates are not
surprising since the use of psychotropic drugs is one of the mainstay strategies
in coping with behavioural and psychiatric problems. The high use of
antipsychotics and the low use of antidepressants of 41.2% and 15.3% of the
PBG and 16.7% and 4.6% of the RG tallies with other studies, although varying
prevalence rates for different samples from community-based facilities have
been found [9, 11, 22].
We observed a tendency to prescribe antipsychotic agents in dosages below 1
DDD in the PBG and the RG. One reason for this could be the reports of
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beneficial effects from using low dosages of antipsychotic agents in
intellectually disabled people with behavioural disorders [23].
In this study, the response rate was approximately 70% for both the problem
behaviour group (PBG) and the random group (RG). Although we did not collect
data from the non-responders, the differences in comparing demographic data
from our sample to the data from the Dutch registration of all group home
residents were relatively minor. It is therefore likely that our results are
representative of the total population of group home residents. However,
selection bias may have been introduced by letting staff select the subjects for
the PBG on their own. This would be the case if the staff had selected a resident
for the PBG according to psychotropic medication use. Although we cannot rule
out this possibility, we instructed staff specifically to look at problematic
behaviour and we did not find any evidence that they did not follow these
instructions.
Subjects in the PBG were younger and had psychotic, anxiety or aggression
symptoms more often. Apparently, the staff found it difficult to deal with this
group since they chose these residents for the PBG. This is emphasised by the
high prevalence of antipsychotics, often prescribed in low dosages and for a
broad spectrum of indications and multiple drug therapy in the PBG. It also
tallies with the results from other studies involving people with intellectual
disabilities, in which an association was found between socially disruptive
behaviour and the prescription of antipsychotics [24, 25]. Heavy use of
antidepressants in the PBG compared to the RG may be explained by the fact
that antidepressants, mainly SSRIs, are sometimes prescribed for people with
poor impulse control or self-injurious behaviour [26].
There is much evidence for the treatment of mood, psychotic, or anxiety
disorders with antidepressants or mood stabilisers, antipsychotics and
anxiolytics [26-29]. Nevertheless, we found a low prevalence of these agents in
subjects with the corresponding symptoms. This finding suggests that a
considerable number of residents with psychiatric or behavioural symptoms is
undertreated. It is most likely that residents’ symptoms were not detected due
to atypical presentation, difficulties in obtaining information and/or limited
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access to psychiatric services [30]. It is also possible that, before resorting to
medication, psychotherapeutic techniques were used to treat the symptoms.
In conclusion, we found considerable differences in the prevalence rates of
psychotropic drugs between a PBG and a RG of group home residents with a
high prevalence of antipsychotics. It is likely that low dosages of antipsychotics
as well as a broad spectrum of drugs were often used for treating socially
disruptive behaviour, as was indicated by the association between psychotic
and aggression symptoms and group membership. Our findings suggest that a
considerable number of residents with psychiatric or behavioural symptoms
were undertreated. In order to determine causal relations between symptoms
and treatment, our findings should be confirmed in another study design with
the data collection on the effectiveness of drug use.
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ABSTRACT
Prevalence rates of psychotropic drug use in people with intellectual disabilities
are high and pharmacotherapy is often attempted with multiple drugs. The
presence of disruptive behaviour is an important factor associated with the use
of psychotropic drugs in this population. We wanted to gain insight into
prevalence and determinants of multiple psychotropic drug use among patients
with mild intellectual disabilities or borderline intellectual functioning with
psychiatric- or behavioural disorders. Therefore, data on psychotropics and
possible determinants of use were retrospectively collected during 1992-1997
in a specialised closed ward of a Dutch general psychiatric hospital. We defined
multiple drug use as concomitant prescription (regular and/or as needed) of a
combination of benzodiazepines/tranquillisers/antipsychotics/anticonvulsants
/antidepressants. Multiple drug use, seen in 48% of the patients, was
associated with a long duration of stay, psychosis, aggressive-, bizarre-,
attention seeking behaviour and involuntary measures. We conclude that it is
likely that difficulties in the management of socially disruptive behaviour are
often countered by multiple drug prescription.
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INTRODUCTION
Studies on the prevalence of mental disorders in people with intellectual
disabilities have shown higher rates than those found in the general population
[1-5]. Recurrent crises because of aggressive and other disruptive behaviours
are strongly associated with psychotropic drug use [6] and pharmacotherapy is
often attempted with multiple drugs in this population [7]. In two recent
surveys the prevalence of the use of more than one psychotropic drug ranged
from 10,7% of 1101 residents of over 120 group homes in the U.S. to about a
quarter of 520 adults living in institutions or community based settings in the
U.K. [8, 9]. Multiple drug use may be in some cases appropriate but can also be
reason for concern in other cases because the more drugs a patient uses the
greater the risk on frequent and serious untoward interactions and side-effects
which can interfere with cognitive and behaviour skills [10, 11].
We performed a retrospective study into the prevalence of multiple psycho-
tropic drug use in patients with mild intellectual disabilities or borderline
intellectual functioning and psychiatric- or behavioural disorders admitted to a
specialised closed ward of a psychiatric hospital. Furthermore we wanted to
gain insight into multiple drugs by analysing possible determinants of use.
MATERIALS AND METHODS
Patients and data collection
Data were retrospectively collected over the years 1992-1997 from a
consecutive sample of 105 patients of 16 years or older concerning their first
admission to a specialised closed ward for people with mild intellectual
disabilities or borderline intellectual functioning and psychiatric- or behavioural
disorders. Patient data (gender, age, level of intellectual functioning, psychiatric
diagnosis, behavioural diagnosis, application of involuntary measures, duration
of stay) and data on the use of psychotropics (type of medication -
benzodiazepines, tranquillisers including droperidol, levomepromazine and
promethazine, antipsychotics, anticholinergics, anticonvulsants, antidepres-
sants and lithium-, dosage, duration of treatment) were extracted from the
medical records by means of a standardised data collection form. The study
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protocol was approved by the Ethics Committee of the University Medical
Center Utrecht.
The ward
The closed ward is part of a general psychiatric hospital and has 24 beds. It
serves an area of four million people coming from the west and middle regions
of the Netherlands. Almost all patients have long histories of recurrent
admissions to psychiatric hospitals or to specialised units of residential settings.
The primary purpose of the ward is to establish a psychiatric- or behavioural
diagnosis and improve the behaviour by prolonged treatment and
rehabilitation.
Psychiatric and behavioural diagnosis
Psychiatric diagnoses according to DSM-III-R/-IV criteria were made during the
first month of hospitalisation by the psychiatrist (MGMC) of the unit.
Additionally, reasons for admission were classified into six categories of
behavioural diagnoses: antisocial-, aggressive- (including selfmutilation- and
suicidal behaviour), withdrawal-, sexually unacceptable-, bizarre- and attention
seeking behaviour.
As a proxy for destructive behaviour during hospitalisation we used the number
of days on which involuntary measures, mostly seclusion, were taken.
Use of psychotropic medication
Multiple drug use was defined as concomitant prescription (regular or as
needed) of: 1) two antipsychotics, 2) antipsychotic and anticonvulsant, 3)
antidepressant and anticonvulsant, 4) antidepressant and antipsychotic, 5)
tranquilliser and benzodiazepine and antipsychotic, 6) tranquilliser and
benzodiazepine and anticonvulsant and 7) tranquilliser and benzodiazepine
and antidepressant. Combinations with anticonvulsants were taken into
account because these agents are often prescribed for psychiatric- or
behavioural disorders in this population. Combinations with anticholinergics
were not taken into account because the addition of these agents to
antipsychotic agents is common because of extrapyramidal side-effects.
During the first month of hospitalisation patients are usually observed for
diagnostic purposes and new treatments based on the results of these
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observations start after this period. Medication used during the first month was
often a continuation of the medication prescribed by the referring physician.
Therefore we defined psychotropic drugs during hospitalisation by excluding
drugs only used during this month.
Medication was coded according to the WHO Anatomical Therapeutic Chemical
(ATC) coding system. Daily exposure to psychotropics was standardised in
number of Defined Daily Doses (DDD-equivalents), a standardised technical
unit of measurement defined as the average dose per day for a drug used for its
main indication in adults [12]. As needed medication was also included in the
analysis.
Analysis
In a nested case-control analysis we compared patients exposed to multiple
psychotropic drugs with patients not exposed to multiple psychotropic drugs
and calculated odds ratios for various possible determinants including gender,
age, level of intellectual functioning, psychiatric diagnosis, behavioural
diagnosis, application of involuntary measures and duration of stay.
Adjustment for possible confounding was performed by an unconditional
logistic regression analysis with multiple drug status as the dependent variable
and possible determinants as independent variables. All analyses were
performed with SPSS package and EGRET.
RESULTS
The study population consisted of 96 patients with a duration of stay of more
than one month. Nine patients with a hospitalisation shorter than one month
were excluded. The patients were predominantly young with a mean age of
26.6 years ranging from 16 to 57 years and a median of 24 years. Male patients
(71.9%) outnumbered female patients. Patients with borderline intellectual
functioning comprised 45.8%, patients with mild intellectual disabilities 49.0%
and patients with moderate intellectual disabilities 5.2% of the population. Of
76 patients data on discharge were available. The remaining 20 were still
hospitalised at the end of the follow-up. The mean length of stay of all 76
patients with completed hospitalisations at the end of the study was 388.3
days ranging from 38 to 1,734 days with a median of 270.5 days. Patients using
regular or as needed psychotropic drugs during hospitalisation had an average
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length of stay of 435.5 days ranging from 38 to 1,734 days with a median of
295 days whereas the average length of stay for patients using no psychotropic
drugs was 196.6 days, ranging form 47 to 538 days with a median of 128 days.
Table 1. Prevalence of regular psychotropic drug use at the first day of stay (referral medication), during
stay and at the day of discharge. At admission and discharge, point prevalence rates were calculated and
during stay the period prevalence was estimated. Of 76 of 96 patients data on discharge were available.
Referral medication
(n = 96) n (%)
Medication during stay
(n = 96) n (%)
Medication at discharge
(n = 76) n (%)
Number of
patients
Average
daily dose*
Number of
patients
Average
daily dose*
Number of
patients
Average
daily dose*
Antipsychotics
Benzodiazepines
Tranquillisers
Antidepressants
Lithium
Anticonvulsants
Anticholinergics
49 (51.0)
30 (31.3)
11 (11.5)
13 (13.5)
1 (1.0)
12 (12.5)
19 (19.8)
1.3
1.5
1.3
1.2
**
1.8
0.7
64 (66.7)
53 (55.2)
20 (20.8)
25 (26.0)
4 (4.2)
18 (18.8)
27 (28.1)
1.1
1.4
2.2
1.1
**
1.4
0.7
42 (55.3)
33 (43.4)
10 (13.2)
6 (7.9)
2 (2.6)
10 (13.2)
12 (15.8)
1.4
1.2
2.2
0.8
**
1.3
0.8
*Number of DDD-equivalents.
**Lithium has no DDD.
Table 1 shows data on the regular use of psychotropic agents. At admission and
discharge point prevalence rates were calculated. During stay the period
prevalence was estimated. At admission 63.5% of the patients used
psychotropic drugs including anticonvulsants, during stay 79.2% and at
discharge 69.7%. Antipsychotics and benzodiazepines were most frequently
used. Pipamperone was the most commonly prescribed antipsychotic and was
used by 19 (19.8%) of all patients and 29.7% of all antipsychotic consumers
during stay. Oxazepam was the most frequently prescribed benzodiazepine,
used by 32 (33.3%) of all patients and 60.4% of benzodiazepine users.
Antipsychotics were prescribed in the widest dose range from 0.1 (thioridazine)
to 2.7 DDD-equivalents per day (haloperidol). In 46 patients (47.9%) multiple
drugs were prescribed during stay. Of the multiple drug users, nine used an
anticonvulsant from which five had a diagnosis of seizure disorder.
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Table 2. Patient parameters and multiple psychotropic drug use*---Adjusted odds ratios calculated
with 95% confidence interval (95% CI). Significant associations are printed in bold.
Multiple
drug users
(n = 46 ) n (%)
No multiple
drug users
(n = 50) n (%)
Crude Odds
Ratio (95% CI)
Adjusted Odds
Ratio (95% CI)
Gender
  Male
  Female
31 (67.4)
15 (32.6)
38 (76.0)
12 (24.0)
1.0 (reference)
1.5 (0.6-3.8)
1.0 (reference)
1.8 (0.5-6.8)
Age (years)
  16-20
  20-30
  >=30
10 (21.7)
22 (47.8)
14 (30.4)
11 (22.0)
23 (46.0)
16 (32.0)
1.0 (reference)
1.1 (0.4-3.0)
1.0 (0.3-2.9)
1.0 (reference)
0.9 (0.2-3.6)
0.7 (0.1-3.4)
Duration of stay  (months)
  1-6
  6-12
  >=12
12 (26.1)
11 (23.9)
23 (50.0)
23 (46.0)
10 (20.0)
17 (34.0)
1.0 (reference)
2.1 (0.7-6.4)
2.6 (1.0-6.6)
1.0 (reference)
1.3 (0.2-7.1)
2.0 (0.6-6.5)
Intellectual functioning
  Borderline
  Mild/moderate
18 (39.1)
28 (60.9)
26 (52.0)
24 (48.0)
1.0 (reference)
1.7 (0.7-3.8)
1.0 (reference)
1.5 (0.4-4.9)
Psychiatric diagnosis
  Psychotic dis.
  Personality dis.
  Substance related dis.
  Impulse control dis.**
17 (37.0)
9 (19.6)
5 (10.9)
10 (21.7)
5 (10.0)
11 (22.0)
4 (8.0)
17 (34.0)
5.3 (1.8-15.9)
1.0 (0.4-2.6)
1.4 (0.4-5.6)
0.5 (0.2-1.2)
13.2 (2.3-74.8)
2.4 (0.5-10.8)
2.4 (0.3-18.6)
1.3 (0.3-6.1)
Behavioural diagnosis
  Antisocial behav.
  Aggressive behav.
  Withdrawal behav.
  Sex. unaccept. Behav.
  Bizarre behav.
  Attent.  seeking behav.
9 (19.6)
33 (71.7)
7 (15.2)
6 (13.0)
9 (19.6)
12 (26.1)
16 (32.0)
26 (52.0)
6 (12.0)
9 (18.0)
2 (4.0)
8 (16.0)
0.5 (0.2-1.3)
2.3 (1.0-5.5)
1.3 (0.4-4.3)
0.7 (0.2-2.1)
5.8 (1.2-28.7)
1.9 (0.7-5.0)
0.7 (0.1-3.2)
7.1 (1.9-27.4)
2.8 (0.4-18.8)
1.7 (0.3-8.2)
15.3 (1.7-137.7)
4.4 (0.9-21.1)
*Multiple drug use: 1) two antipsychotics, 2) antipsychotic and anticonvulsant, 3) antidepressant
and anticonvulsant, 4) antidepressant and antipsychotic, 5) tranquilliser and benzodiazepine and
antipsychotic, 6) tranquilliser and benzodiazepine and anticonvulsant and 7) tranquilliser and
benzodiazepine and antidepressant.
**Included are: attention deficit- and disruptive behaviour disorders and impulse control disorders
not elsewhere classified.
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In Table 2 determinants of multiple psychotropic drug use are listed. Psychotic
disorder, aggressive behaviour and bizarre behaviour were significantly
associated with multiple psychotropic drug use. Attention seeking behaviour
was also associated with multiple drug use, although not statistically
significant as was the association with duration of stay. Since we were
interested in determinants of multiple psychotropic drug use we looked at
involuntary measures taken on days before multiple drug prescription. Only
patients using multiple drugs after the first week of admission (27) were
entered into this analysis. Involuntary measures were associated with multiple
drug use with an odds ratio of 2.3 (95% confidence interval: 0.7-8.4) (Table 3).
Table 3. Involuntary measures -in percentages of days foregoing multiple drug use- and
multiple drug use* after the first week of admission. Odds ratios are calculated with 95%
confidence interval (95% CI).
Multiple drug
users
(n = 27) n (%)
No multiple drug
users
(n = 50) n (%)
Odds Ratio
(95% CI)
Involuntary measures
  No measures
  Measures < 10%
  Measures > 10%
18 (66.7)
 3 (11.1)
 6 (22.2)
41 (82.0)
 5 (10.0)
 4 (8.0)
1.0 (reference)
0.7 (0.2-3.2)
2.3 (0.7-8.4)
*Multiple drug use: 1) two antipsychotics, 2) antipsychotic and anticonvulsant, 3)
antidepressant and anticonvulsant, 4) antidepressant and antipsychotic, 5) tranquilliser
and benzodiazepine and antipsychotic, 6) tranquilliser and benzodiazepine and
anticonvulsant and 7) tranquilliser and benzodiazepine and antidepressant.
DISCUSSION
In the present study, we found that during their hospital stay approximately
80% of the patients used one or more psychotropics including anticonvulsants
with highest use of antipsychotics, prescribed to 66.7%. The use of
psychotropics was high compared to other studies among people with
intellectual disabilities in institutions in which prevalence rates from 44 to 60%
were found [13]. When anticonvulsants were excluded only slightly lower
prevalence rates were found. High prevalence rates are not surprising because
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prerequisites for admission on our ward are psychiatric- and behavioural
disorders. The relative high use of antipsychotics is in agreement with other
studies although different prevalence rates for different samples of people
were found [14-17].
Multiple drug use was associated with aggressive behaviour. There was also an
association with attention seeking behaviour and involuntary measures,
although not significant possibly due to small numbers. Many patients
admitted to the ward have long histories of recurrent admissions to psychiatric
hospitals and to specialised units of residential settings and it is likely that our
finding indicate difficulties in the management of patients with socially
disruptive behaviour. This is underlined by the finding that psychotropic drugs
were used in high dosages and the tendency to prescribe multiple drugs in
patients with a duration of stay of more than a year. The association between
psychotic disorder and multiple medication was not surprising because this
disorder is often accompanied with agitation. Therefore, combinations of
antipsychotics with benzodiazepines and tranquillisers are frequently used.
Another explanation for the association between psychotic disorder and
multiple drug use is the fact that among patients with learning disabilities and
aggressive behaviour sometimes an underlying psychotic disorder is suspected
whereas with a formal psychiatric evaluation no psychotic symptoms are
observed. The complex treatment of patients with socially disruptive behaviour
is emphasised by the results of other studies among people with learning
disabilities in which an association between such behaviour and the use of
antipsychotic drugs was found [9, 18, 19]. The association between bizarre
behaviour and multiple drug use may be explained by the fact that it is difficult
to interpret this behaviour and that it may be related to severe disorders such
as autistic disorder and psychotic disorder for which a broad spectrum of
psychotropics are prescribed.
We did not consider the combined use of antipsychotics with anticholinergics
as multiple psychotropic drug use as this combination is commonly used
because of extrapyramidal adverse effects. Nevertheless, it is possible that
many patients who were maintained on long-term antipsychotics, actually no
longer require these agents, which may be a source of cognitive side-effects or
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elevated mood in sensitive patients [20]. We found that four of nine multiple
drug users who used anticonvulsants had no seizure disorder. Anticonvulsants
are often used for psychiatric and behavioural purposes [21].
In this study, no effect of gender, age and level of intellectual functioning on
multiple psychotropic drug use was found. The lack of a gender effect is
consistent with most studies looking at this variable (8,13,16]. Concerning age
and psychotropic use, some researchers found no relation whereas others have
found that older people use more psychotropics [8,13,16]. Jacobson found that
young and middle aged adults received higher rates of psychotropic medication
than children, adolescents and older people [22]. Inconsistent results are
reported concerning the association of level of intellectual functioning and
psychotropic drug use [8,13,16].
In conclusion, we found a prevalence of multiple psychotropic drug use of 48%
in this population. A clear association between multiple drugs and socially
disruptive behaviour was found indicating that difficulties in the management
of this behaviour is a common problem. More detailed investigations into the
rational of prescribing multiple drugs in settings for people with intellectual
disabilities are needed.
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PSYCHOTROPIC DRUG USE: PRACTICE VERSUS EVIDENCE
A main finding of this thesis is the observation that physicians - in an effort to
provide optimal care for their patients - ‘struggle’ with prescribing psychotropic
drugs for many reasons. The variety of clinical settings that was studied in this
thesis all comprised a highly complex patient population, with multiple
psychiatric and somatic disorders. Another challenge for the prescribing
physician is that present choice of available treatments may involve the use of
drugs or procedures such as seclusion that have not been properly tried and
tested. Randomised controlled trials (RCTs) of psychotropic drugs have provided
little evidence for their efficacy and safety in study populations that are
representative of those treated in actual clinical practice [1, 2]. Older patients,
women of child bearing age or pregnant, and patients with mixed diagnoses
and co-morbidity with (severe) personality disorders are excluded from most
trials. Patients also often drop out because they experience adverse effects.
Recently, Zimmerman et al [3] found that RCT patients only represent a
minority of the patients with major depressive disorder treated in actual
clinical practice: only 14% of those treated in daily practice would meet the
inclusion criteria of a typical RCT on antidepressants. So, the results of studies
on only a small fraction of patients with depressive disorder are generalised to
all patients, assuming the effectiveness and safety are comparable.
The difficulties in conducting RCTs are also true for the populations we studied.
Recent reviews on the use of antipsychotics in behavioural disorders and in
schizophrenia in intellectually disabled adults concluded that there is a great
lack of good quality trials conducted in this field [4, 5]. In addition, Cure and
Carpenter [6] reviewed RCTs evaluating droperidol use in people with
suspected acute psychotic illnesses and disturbed behaviour. The review was
only able to include a few RCTs and concluded that the use of droperidol in this
patient group is founded on clinical experience rather than on evidence from
RCTs. In a systematic review of the use of sedative agents in intensive care
settings, it was concluded that large RCTs studying the efficacy of different
agents for short-term and long-term sedation are warranted [7]. There is
insufficient evidence for the use of these drugs in intensive care settings.
Evidence-based treatment is the paradigm of current medicine, while,
especially in psychiatry, there are not enough valid data available, due to lack of
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studies, poorly designed or executed studies, and, most frequently,  the huge
differences between patients studied in RCTs and those treated in daily
practice.
UNDERTREATMENT VERSUS POLYPHARMACY
We have found two examples of suboptimal treatment in psychiatry:
undertreatment of patients in need of pharmacotherapy; and possible
overtreatment in the form of polypharmacy (the use of psychotropic drugs
concomitantly).
This thesis presented studies on the prevalence of psychotropic drug use in a
variety of clinical settings. We found that many patients with psychiatric or
behavioural disorders appear to be undertreated with psychotropic drugs. In
group homes, antidepressants or mood stabilisers, antipsychotics and
anxiolytics were used infrequently in patients with affective, psychotic or
anxiety symptoms. In psychiatric admission wards, a considerable number of
patients with psychotic disorders did not use antipsychotics at the beginning of
their hospitalisation, and consequently many were later secluded. Thus,
undertreatment can lead to prolonged suffering and may result in more severe
outcomes.
In two settings for the intellectually disabled, group homes and a specialised
psychiatric ward, we observed a very high prevalence of concomitant use of
psychotropic drugs. In studies conducted in other psychiatric settings, frequent
polypharmacy was also observed [8]. Although, in many instances, the use of
more than one psychotropic drug may be necessary and reasonable, irrational
polypharmacy also frequently occurs [9]. In a recent publication, several
circumstances that could lead to irrational use are mentioned [9]. The first
circumstance concerns a patient doing poorly where the physician adds
medication but is afraid to withdraw any of the other ineffective drugs. The
second involves treatment of individual symptoms instead of relating
symptoms primarily to the (main) diagnosis. Other circumstances may result
from a failed cross-titration of two psychotropic drugs, inadequate dosing in
cases of monotherapy, inadequate knowledge or lack of attention to
pharmacodynamic or pharmacokinetic aspects of drugs, the wish to hasten a
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therapeutic response and not well-studied recommendations of others. Some
aspects play a role in the treatment of intellectually disabled people with
psychiatric disorders. Polypharmacy may increase the risk of morbidity and
mortality [9]. Possibly, untoward interactions and adverse effects are more
prevalent in the population of intellectually disabled compared to the normal
population [10, 11].
PSYCHOTROPIC DRUG USE VERSUS SECLUSION
Patients with severe disruptive or aggressive behaviour are common in mental
health care [12]. Often, difficulties with pharmacotherapy occur in these
patients due to poor compliance or other problems related to drug intake. The
disruptive or aggressive behaviour itself may influence the choice of
pharmacotherapy used in these patients [13]. We found that disruptive
behaviour or aggression is an important factor associated with psychotropic
drug use. It is likely that psychotropics prescribed in the 'struggle' of clinical
practice are used not only to treat patients, but also to diminish danger for the
patient or his environment. In group homes, socially disruptive behaviour was
associated with antipsychotics and antidepressants. In a specialised ward for
intellectually disabled adults, we found that a broad spectrum of drugs was
used concomitantly to treat patients with socially disruptive behaviour.
Although many psychotropics, including antipsychotics, benzodiazepines,
antidepressants, lithium and anticonvulsants, are used for their anti-aggressive
properties, there is little evidence available for their effectiveness for this
indication [14, 15]. Aggression is difficult to study because it is a heterogeneous
phenomenon associated with many biological, psychological and social factors.
As a consequence of the lack of evidence, most regulatory agencies have not
approved psychotropics for the treatment of aggression [14, 15]. In contrast,
several classical antipsychotics are registered in the Netherlands for the
treatment of (psychotic) agitation during the 1960s and 1970s, during which
time the requirements were less stringent [16].
Seclusion is applied to more than a quarter of newly admitted patients on
psychiatric admission wards. It is likely that seclusion is considered less
infringing than involuntary medication, but in the end, (forced) pharma-
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cological treatment seems inevitable for a substantial proportion of secluded
psychotic patients. As mentioned in Chapter 2.1, antipsychotic drugs are
considered essential in both international and Dutch guidelines for the
treatment of psychosis [17, 18]. So far, there has been no study evaluating the
effectiveness of seclusion [19]. The choice of antipsychotics in aggressive
patients with (psychotic) disorders can be considered more supported by valid
data than the choice of seclusion. However, in addition to evidence, this choice
also depends on other factors including restrictions of the Dutch law and the
physicians' and patients' knowledge of and attitude towards psychotropics and
seclusion.
CLASSICAL VERSUS ATYPICAL ANTIPSYCHOTICS
The 1998 Dutch guidelines for treatment of patients with psychotic disorders
have not decided between classical or atypical antipsychotics for first-line
treatment [18]. This debate on the choice of first-line treatment for psychosis is
also still ongoing in literature [20-27].
We found that many psychotic patients initially use short-acting parenteral
classical antipsychotics, mainly zuclopenthixol acetate. This is an interesting
finding as there is no evidence that zuclopenthixol acetate is more effective
than 'standard' care in controlling aggressive/disorganised behaviour or acute
psychotic symptoms or in preventing adverse effects. Probably, it is more often
used in urgent situations compared to other parenteral antipsychotics because
of its 2-3 day action and low frequency of administration [28].
Regarding the choice of classical or atypical oral antipsychotics in newly
admitted patients, severity of psychiatric illness was not found to be a
determinant. However, if patients start with parenteral classical antipsychotics,
they frequently continue oral treatment with the classical antipsychotics. The
most likely reason is that short-acting parenteral antipsychotics are only
available for the classical and not the atypical antipsychotic drugs. Therefore, it
is likely that the coming availability of intramuscular atypical antipsychotics
will rigorously change prescription patterns. Another factor that affects the
choice of antipsychotics is (prior) occurrence of extrapyramidal syndromes. It
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has been found that atypical antipsychotics tend to be selectively prescribed to
patients with a history of extrapyramidal syndromes [29].
IMPLICATIONS OF THE STUDY
Research implications
RCTs into effects of psychotropic drugs in populations or indications that are
difficult to study are warranted, even when such trials in themselves would not
be enough to obtain formal approval for marketing. However, is this a realistic
challenge? Conducting RCTs is extremely costly [30]. After registration for a
specific indication, pharmaceutical companies may have only limited interest in
conducting studies for other indications and in other populations. One reason
for this is that the potential market size is often limited. Furthermore, the
manufacturer can only be held liable for severe adverse effects that occur in
patients with a registered indication, thus reducing the interest to register the
drug for indications in high-risk patients [31].
Observational studies may play an important role in filling the gap between
evidence based on RCTs and clinical practice. Because of lack of randomisation
in observational studies, it is not possible to measure efficacy of psychotropic
agents and, because of ‘confounding by indication’, the evaluation of
effectiveness of one drug compared to another drug must be interpreted
carefully. In addition to RCTs, however, well designed pharmacoepidemiological
studies with the use of standardised measurements may contribute to evidence
of psychiatric treatments especially in complex populations such as the
population of intellectually disabled and for 'difficult indications' such as
aggression. This may be even more important when studying treatments, such
as using antipsychotics related to seclusion in RCTs, is impossible because of for
example ethical reasons.
Databases may provide data to conduct these pharmacoepidemiological
studies. In most existing databases, however, data of psychiatric admissions are
lacking leading to missing of patients or to gaps of relevant data. It is therefore
useful, in addition to these existing databases, to develop advanced databases
containing data on psychotropic drug use and indications for this use, patient-
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related and laboratory data with the collaboration of pharmacists, physicians
and other professionals in psychiatric inpatient and outpatient settings.
The results of this thesis stress the need for research on the effectiveness and
the adverse effects of seclusion. The finding that (forced) antipsychotic
treatment early during hospitalisation will probably prevent patients from
being secluded should be confirmed in other studies. It is also important to
discern whether our findings on the association between antipsychotics and
seclusion are typical for the Dutch mental health care system. We recommend
that studies on the association between the use of psychotropics and seclusion
are conducted on admission wards with different cultures of clinical practice.
Patients who are admitted to acute admission wards often have a history of
outpatient psychotropic drug use. Therefore, future studies on determinants
for the choice of atypical or classical antipsychotics should also consider the
psychotropic drug use prior to the psychiatric admission. In addition, history of
extrapyramidal syndromes should be evaluated in the context of appropriate
choice of antipsychotics.
Clinical implications
Evidence for prescribing (multiple) psychotropics for aggression is scarce and
experimental treatments should be evaluated using a wide range of
observational methods to provide more comprehensive and objective ratings of
patients' progress in clinical practice [9].
If there are good reasons to use forced medication, it is possible to do so within
the limits of the Dutch law. In avoiding seclusion (a non-evidence based
intervention), psychiatrists should apply forced medication more frequently.
Against the background of the discussion in the Netherlands on involuntary
treatment [32], the results of this study also support a modification of the
Dutch law 'Compulsory admission into psychiatric hospitals' (BOPZ act) with
involuntary treatment applied more easily.
A diversity of factors may be responsible for undertreatment in residents with
psychiatric or behaviour disorders living in group homes as mentioned in
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Chapter 4.1. It is likely that better recognition of (atypical) symptoms and easier
access to psychiatric services may prevent intellectually disabled residents from
some unnecessary suffering. Finally, pharmaco-epidemiological research of
psychotropic drug use teaches us more about clinical practice in which
physicians and patients struggle for optimal treatment.
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INTRODUCTION
The prescribing of psychotropic drugs in clinical practice is influenced by a
variety of factors, including the indications for treatment (both registered and
off-label) and reflecting changes in guidelines and attitudes in psychiatry with
its current emphasis on biological aspects and evidence-based mental health
care. Epidemiological factors such as the prevalence of psychiatric disorders
and cultural values such as the role of individual autonomy in our Western
world also play a role. The physician, in collaboration with the patient, has to
make choices on (psychopharmacologic) treatment. Choosing a treatment is
often difficult especially for severely ill patients with psychiatric and somatic
co-morbidity as these patients are routinely excluded from randomised
controlled trials (RCTs) resulting in limited evidence for drug efficacy in this
patient group. Studies on the determinants of psychotropic drug use may help
to explore the ‘gap’ between evidence and clinical practice.
The main objectives of this thesis were to establish the prevalence of
psychotropic drug use as well as possible determinants associated with its use
in multiple clinical settings: psychiatric admission wards, an intensive care unit
and two settings for the intellectually disabled.
PSYCHOTROPIC DRUG USE IN PSYCHIATRIC ADMISSION WARDS
Antipsychotic drugs are essential in the treatment of patients suffering from
psychotic disorders. The introduction of atypical antipsychotics has changed
treatment options dramatically. Although the newer agents seem to be
superior with regard to the lower risk of extrapyramidal symptoms, they have
been associated with other side effects such as weight gain.
In Chapter 2.1, we evaluated the question which class of antipsychotics
(classical versus atypical) is prescribed preferentially in newly admitted patients
on psychiatric wards and the determinants affecting this decision. In a
retrospective cohort design, using the drug database and clinical database of
the participating hospitals, linked anonymously through record linkage
methodology, patients were followed from date of admission until discharge
from hospital during 1997-1999. We found that the most frequently prescribed
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oral antipsychotic drugs were classical agents: zuclopenthixol (33.7%),
pimozide (13.4%) and haloperidol (12.6%). The proportion of atypical agents
used was 27.8%, consisting of clozapine (1.9%), olanzapine (14.8%) and
risperidone (11.1%). No statistically significant difference was found between
patients with varying severity of disease, as indicated by GAF-score and type of
ward (open versus closed). Initial choice for short-acting parenteral classical
antipsychotics was significantly associated with follow-up prescriptions of oral
classical antipsychotics. Therefore, we predict that upcoming introductions of
short-acting parenteral formulations of atypical agents are likely to have a
large impact on the subsequent oral antipsychotic treatment.
Seclusion is one of the strategies to cope with disruptive and violent behaviour
in psychiatric patients. No studies on the effectiveness of seclusion are
available and the relationship between psychotropics and the application of
seclusion has hardly been studied.
In Chapter 2.2, we looked at the temporal relationship between the use of
antipsychotics and seclusion. Again, data extracted from a patient database
linked to the hospital pharmacy database were retrospectively collected over
the years 1997-1999. The study population consisted of 996 newly and
consecutively admitted patients of 16 years or older with a complete first
hospitalisation record of four days or longer on one of the participating
admission wards. A high prevalence of seclusion was found: over a quarter
(28.6%) of the patients was secluded at least once during their hospitalisation.
This statistic may be related to the Dutch situation where involuntary
hospitalisation does not mean that the patient has to accept the proposed
medical treatment. Young age, a low GAF (Global Assessment of Functioning)
score indicating major impairment in functioning, involuntary hospitalisation
and a diagnosis of bipolar disorder (manic episode) were all factors significantly
associated with seclusion. In contrast with other studies, a diagnosis of
psychotic disorder was not associated with seclusion. It was found that
antipsychotic treatment in patients with psychotic disorders was significantly
associated with a delay of seclusion with an adjusted hazard ratio of 0.6 (95%
confidence interval: 0.3-1.0) and, although not statistically significant, with a
lower risk of seclusion with a relative risk of 0.7 (95% confidence interval: 0.5-
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1.2). Furthermore, in a substantial proportion of the patients, antipsychotic
therapy was only initiated during or directly following seclusion with a relative
risk of 2.0 (95% confidence interval: 1.2-3.4). This suggests that, in patients with
psychotic disorders, not using antipsychotics is associated with aggression or
violence for which seclusion is needed. Pharmacological treatment seems
inevitable for a substantial proportion of secluded psychotic patients and its
earlier use might have prevented patients from being secluded.
PSYCHOTROPIC DRUG USE IN A GENERAL INTENSIVE CARE UNIT
Although psychiatric disorders frequently occur in intensive care settings and
psychotropic drugs are often used, little is known about the determinants
associated with psychotropic drug use in an intensive care unit. The fluctuating
course of critical illness complicates the assessment of individual needs for
psychotropic drugs along with highly variable patterns of drug metabolism and
elimination.
In Chapter 3.1, we studied determinants of psychotropic drug use in a general
intensive care unit (ICU). We retrospectively collected data for the first three
months of 1995 from a consecutive sample of 137 patients aged 18 years or
older. To deal with varying lengths of hospitalisation, ‘bed-days’ were taken as
unit of analysis. The odds ratios for the use of benzodiazepines, antipsychotics
or both were calculated comparing exposed days with unexposed days for
gender, age, length of stay, reason for admission and disease severity indicated
by APACHE (Acute Physiologic and Chronic Health Evaluation)-II scores. The
prevalence of psychotropic drug use was 42.3%. Benzodiazepines were used in
35.8% of the patients, frequently at a high dosage (average dosage of 9.9 DDDs
per day). Antipsychotics were prescribed in 17.5% of all patients, typically in low
dosages with an average dosage of 0.5 DDDs per day. The association of high
APACHE-II scores, a long ICU stay and an admission for non-surgical reasons
with psychotropic drug use may be an indication that severely ill patients are
likely to suffer from a delirium. An alternative explanation is that combined use
of benzodiazepines and antipsychotics may prolong the stay in the ICU because
of excessive sedation with cognitive impairment.
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In this study, patients who used psychotropic drugs (cases) acted as their own
controls because periods of drug exposure were compared to those of non-
exposure. In this analysis, no corrections were made with the fact that
observations were correlated.
In Chapter 3.2, we compared this design with a logistical binomial model to
adjust for correlated measures, or cluster effects through repeated measures.
We found that, although adjustment did not result in major changes in the
odds ratios found, adjustment has greater effect with more observations per
cluster.
PSYCHOTROPIC DRUG USE IN SETTINGS FOR PEOPLE WITH INTELLECTUAL
DISABILITIES
In previous studies, prevalence of psychotropic and/or anticonvulsant drug use
in intellectually disabled persons was high, ranging from 44-60% in institutions
and 35-45% in community settings. Recurrent crises because of aggressive and
other disruptive behaviour are strongly associated with psychotropic drug use
and pharmacotherapy attempts with multiple drugs. We conducted two
studies on the use of psychotropic drugs among intellectually disabled patients.
In Chapter 4.1,  the point prevalence of psychotropic drug use in a problem
behaviour group (PBG) of intellectually disabled group home residents was
compared to a random group (RG) of residents and possible determinants of
group membership were studied. From all group homes in The Netherlands,
573 problematic residents were selected by staff (one resident from each
home) and 1479 residents were randomly sampled from all the homes. Mental
disorders were measured with Dutch versions of the Reiss Screen for
Maladaptive behavior and the Psychopathology Instrument for Mentally
Retarded Adults. We found that, as expected, psychotropic drug use was much
higher in residents of the group homes with behavioural problems compared to
a random group of residents. Psychotropics, excluding anticonvulsants, were
used by 52.6% of the problem behaviour group and by 22.8% of the random
group. In the PBG, 17.3% used three or more concomitantly prescribed drugs
and in the RG, 7.3%. Three or more categories of psychotropic drugs were used
concomitantly by 11.1% of the PBG and 2.8% of the RG. A high prevalence of
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antipsychotics (41.2% in the PBG; 16.7% in the RG), often prescribed at low
dosages and for a broad spectrum of indications, was found. Low dosages of
these agents were prescribed probably because beneficial effects of low
dosages of these agents have been reported in intellectually disabled people
with behavioural problems. It was found that young age, psychotic, anxiety and
aggression symptoms were significantly associated with the PBG. It is likely
that staff finds it difficult to deal with this group of residents, which would be
in agreement with other studies. Remarkably, a low prevalence of
antidepressants, mood stabilisers, antipsychotics and anxiolytics in patients
with the corresponding symptoms was found. This suggests that a considerable
number of residents remain undertreated.
In Chapter 4.2, we examined the prevalence and possible determinants of
multiple psychotropic drug use in patients with mild intellectual disabilities or
borderline intellectual functioning and psychiatric or behavioural disorders
admitted to a specialised closed ward for prolonged treatment and
rehabilitation. Data on psychotropics and possible determinants of use were
retrospectively collected for the years 1992-1997 from a consecutive sample of
96 patients of 16 years or older concerning their first admission of at least one
month. Multiple drug use was defined as concomitant use of a combination of
benzodiazepines / tranquillisers / antipsychotics / anticonvulsants / antidepres-
sants. We found that the point prevalence of psychotropic drugs at admission
was 63.5%, the period prevalence during hospitalisation was 79.2% and the
point prevalence at discharge was 69.7%. Of all psychotropics, use of
antipsychotics during admission (66.7%) was highest as seen in previous
studies. Multiple drug use was found in half of the patients. Psychotropics were
used in high dosages and there was a tendency to prescribe multiple drugs for
patients with duration of stay longer than a year. Furthermore, psychotic
disorder, aggressive, bizarre, attention seeking behaviour and involuntary
measures were associated with multiple psychotropic drug use. Many patients
have long histories of recurrent admissions to psychiatric hospitals and
specialised units of residential settings. It is likely that our findings, especially
the association with aggressive and attention seeking behaviour, indicate
difficulties in the management of patients with socially disruptive behaviour.
This is emphasised by the association of multiple drug use with psychotic
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disorder and is in line with other studies that found an association between
such behaviour and the use of antipsychotics.
In conclusion, we investigated patterns of psychotropic drug use and identified
possible determinants for their use in a variety of clinical settings. In these
settings, physicians deal with complex patients for whom the evidence of the
effectiveness and safety of available treatments is scarce. The studies show
that observational pharmacoepidemiological studies may play an important
role in analysing the gap between the evidence derived from non-
representative RCTs and the complex patients in routine clinical practice.
Chapter 7
Samenvatting
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INLEIDING
Allerlei factoren hebben invloed op het voorschrijven van psychofarmaca in de
klinische praktijk zoals geregistreerde en off-label indicaties van geneesmid-
delen, de veranderende opvattingen over psychiatrische stoornissen, de huidige
nadruk op biologische psychiatrie en ‘evidence based’ geestelijke gezondheids-
zorg. Daarnaast spelen epidemiologische factoren, met name de prevalentie
van psychiatrische stoornissen, en culturele waarden zoals de nadruk op
individuele autonomie in onze Westerse wereld een rol. In deze complexe
situatie is het de arts die, in overleg met de patiënt, keuzes moet maken in de
(psychofarmacologische) behandeling. Dit is met name moeilijk bij ernstige
zieke psychiatrische patiënten met psychiatrische en somatische co-
morbiditeit. Over de farmacologische behandeling van dergelijke patiënten is
relatief weinig bekend omdat zij meestal uitgesloten worden van gerandomi-
seerd klinisch onderzoek (randomised controlled trial: RCT). Hierdoor is er
weinig bewijs voor de werkzaamheid van geneesmiddelen in deze patiënten-
groep ondanks dat psychofarmaca in de dagelijkse klinische praktijk veel
worden voorgeschreven. Observationeel farmaco-epidemiologisch onder-zoek
naar determinanten van het gebruik van psychofarmaca kan behulpzaam zijn
in het verkennen van de kloof tussen wetenschappelijk bewijs en deze praktijk.
In dit proefschrift worden diverse onderzoeken beschreven naar de prevalentie
van psychofarmacagebruik en naar mogelijke determinanten die van invloed
zijn op het gebruik in verschillende klinische populaties: op psychiatrische
opnameafdelingen, een intensive care unit en twee voorzieningen voor mensen
met een verstandelijke handicap.
PSYCHOFARMACAGEBRUIK OP PSYCHIATRISCHE OPNAMEAFDELINGEN
Antipsychotica zijn onontbeerlijk in de behandeling van patiënten die lijden aan
psychotische stoornissen. Door de introductie van atypische antipsychotica zijn
de behandelingsmogelijkheden aanzienlijk uitgebreid. Hoewel de nieuwere
middelen voordelen lijken te hebben wat betreft de kans op extrapiramidale
symptomen, kunnen ze wel andere bijwerkingen zoals gewichtstoename tot
gevolg hebben.
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In Hoofdstuk 2.1 wordt een onderzoek beschreven naar welk type
antipsychoticum (klassiek versus atypisch) bij voorkeur wordt voorgeschreven
aan nieuw opgenomen patiënten op psychiatrische opnameafdelingen en
welke factoren deze keuze beïnvloeden. In een retrospectief cohort onderzoek
werden patiënten die gedurende de jaren 1997-1999 voor de eerste maal
opgenomen werden van opname tot ontslag gevolgd. Hierbij werd gebruik
gemaakt van de geneesmiddelendatabase van de deelnemende ziekenhuizen
die anoniem gekoppeld werd aan de patiëntendatabase. De meest voorge-
schreven orale antipsychotica waren klassieke middelen: zuclopenthixol
(33,7%), pimozide (13,4%) en haloperidol (12,6%). Ruim een kwart (27,8%) van
de 522 nieuw opgenomen patiënten die met een antipsychoticum behandeld
werd, gebruikte in eerste instantie een atypisch middel waarbij olanzapine door
14,8% van de patiënten, risperidon door 11,1% en clozapine door 1,9% werd
gebruikt. Ernst van de ziekte zoals gemeten door de GAF (Global Assessment of
Functioning) score en type opnameafdeling (open of gesloten) was niet van
invloed op de keuze tussen klassieke of atypische middelen. Het bleek dat
wanneer in eerste instantie voor kortwerkende klassieke parenterale anti-
psychotica gekozen wordt, daarna vaak klassieke orale antipsychotica worden
voorgeschreven. De op handen zijnde introductie van kortwerkende
parenterale atypische antipsychotica zal daarom naar alle waarschijnlijkheid de
keuze van het orale antipsychoticum dat vervolgens wordt voorgeschreven
(klassiek of atypisch) sterk beïnvloeden.
Separatie is een van de maatregelen die genomen kan worden om
ontwrichtend en agressief gedrag van psychiatrische patiënten te hanteren. Er
is geen onderzoek bekend naar de werkzaamheid van separatie. Het verband
tussen het voorschrijven van antipsychotica en separatie is eveneens
nauwelijks onderzocht.
In Hoofdstuk 2.2 wordt een onderzoek beschreven naar de relatie tussen het
voorschrijven van antipsychotica en separatie. Opnieuw werden gegevens van
de patiënten database gekoppeld aan de apotheek database retrospectief
verzameld van 1997-1999. De onderzoekspopulatie bestond uit 996
achtereenvolgens opgenomen patiënten van 16 jaar en ouder die voor de
eerste maal vier of meer dagen opgenomen waren op een opnameafdeling.
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Separatie werd vaak toegepast: meer dan een kwart (28,6%) van de patiënten
werd tenminste een keer gesepareerd tijdens de opname. Dit heeft
waarschijnlijk deels te maken me de Nederlandse situatie: een onvrijwillige
opname betekent niet dat een patiënt gedwongen kan worden tot een
(medicamenteuze) behandeling. Een jonge leeftijd, een lage GAF score wijzend
op een laag niveau van functioneren, onvrijwillige opname en een bipolaire
stoornis (manische episode) waren significant geassocieerd met separatie. In
tegenstelling tot diverse andere onderzoeken bleek er geen relatie tussen de
diagnose psychotische stoornis en het toepassen van separatie te zijn. Anti-
psychotische behandeling was significant geassocieerd met een latere
toepassing van separatie met een gecorrigeerde hazard ratio van 0,6 (95%
betrouwbaarheidsinterval: 0,3-1,0) en, hoewel niet significant, met een lager
risico op separatie met een relatief risico van 0,7 (95% betrouwbaarheids-
interval: 0,5-1,2). Bovendien bleek dat in een aanzienlijk deel van de patiënten
met antipsychotica begonnen wordt tijdens of kort na separatie met een
relatief risico van 2,0 (95% betrouwbaarheidsinterval: 1,2-3,4). Waarschijnlijk is
agressie of geweld geassocieerd met psychotische patiënten die geen
antipsychotica gebruiken waarbij vervolgens separatie wordt toegepast. Een
behandeling met antipsychotica lijkt onvermijdelijk voor een aanzienlijk deel
van de psychotische patiënten en mogelijk kan het gebruik van deze middelen
aan het begin van de opname separatie voorkomen.
PSYCHOFARMACAGEBRUIK OP EEN ALGEMENE INTENSIVE CARE AFDELING
Hoewel psychiatrische aandoeningen vaak voorkomen op intensive care
afdelingen en psychofarmaca frequent gebruikt worden, is er weinig bekend
over de factoren die het gebruik van deze middelen op deze afdelingen
beïnvloeden. Het vaak stormachtige beloop van de ernstige aandoeningen, het
sterk wisselende metabolisme en de wisselende uitscheiding van geneesmid-
delen bemoeilijken de beoordeling van de individuele behoefte aan
psychofarmaca.
In Hoofdstuk 3.1 wordt een onderzoek beschreven naar determinanten van
psychofarmacagebruik op een algemene intensive care afdeling. Retrospectief
werden gegevens verzameld over de eerste drie maanden van 1995 van 137
patiënten van 18 jaar en ouder. Omdat de duur van de opname van de
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patiënten nogal uiteenliep, werden ‘bed-dagen’ als analyse eenheid gebruikt.
De odds ratios van het gebruik van benzodiazepines, antipsychotica of beiden
werden berekend waarbij de dagen waarop psychofarmaca werden gebruikt
vergeleken werden met dagen waarop deze middelen niet werden gebruikt
voor geslacht, leeftijd, opnameduur, reden voor opname en ernst van de
aandoening aangeduid door APACHE (‘Acute Physiologic and Chronic Health
Evaluation’)-II scores. De prevalentie van psychofarmacagebruik was 42,3%.
Benzodiazepines werden door 35,8% van de patiënten in hoge doseringen
(gemiddeld 9,9 DDDs per dag) gebruikt. Antipsychotica werden voorgeschreven
aan 17,5% van de patiënten in lage doseringen van gemiddeld 0,5 DDDs per
dag. Het gebruik van psychofarmaca was geassocieerd met een hoge APACHE-II
score, een langdurige opname en een opname voor niet chirurgische redenen.
Het is aannemelijk dat deze ernstig zieke patiënten een groot risico lopen op
een delier. Daarnaast is het mogelijk dat gecombineerd gebruik van
benzodiazepines en antipsychotica het verblijf op de intensive care verlengd
vanwege overmatige sedatie met verslechtering van de cognitieve functies.
In het bovengenoemde onderzoek fungeerden patiënten die psychofarmaca
gebruikten (cases) als hun eigen controles omdat dagen waarop patiënten
psychofarmaca gebruikten, werden vergeleken met dagen waarop geen
psychofarmaca werden gebruikt.
Aanvullend op dit onderzoek wordt in Hoofdstuk 3.2 bovengenoemde onder-
zoeksopzet vergeleken met een andere opzet: een logistisch-binomiaal model
om te corrigeren voor gecorreleerde waarnemingen of cluster effecten door
herhaalde metingen. Aangetoond wordt dat hoewel correctie niet leidde tot
grote veranderingen in de odds ratios, correctie van grotere invloed was naar
mate er meer observaties per cluster plaatsvonden.
PSYCHOFARMACAGEBRUIK IN VOORZIENINGEN VOOR VERSTANDELIJK GEHAN-
DICAPTEN
Uit eerdere onderzoeken bij verstandelijk gehandicapten is gebleken dat de
prevalentie van psychofarmaca en/of anti-epileptica gebruik hoog is met een
spreiding van 44-60% in intramurale woonvoorzieningen en van 35-45% in
meer maatschappelijk geïntegreerde voorzieningen. Terugkerende crisis-
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situaties vanwege agressief of ander ontwrichtend gedrag zijn in sterke mate
geassocieerd met het gebruik van psychofarmaca en polyfarmacie komt veel
voor.
In Hoofdstuk 4.1 en 4.2 worden twee onderzoeken beschreven naar het gebruik
van psychofarmaca door mensen met een verstandelijke handicap.
In Hoofdstuk 4.1 werd de punt prevalentie van het gebruik van psychofarmaca
bij verstandelijk gehandicapte bewoners van gezinsvervangende tehuizen met
gedragsproblemen vergeleken met een aselecte groep van bewoners. Factoren
die mogelijk samenhingen met een van beide populaties werden bestudeerd.
Uit alle gezinsvervangende tehuizen in ons land werden 573 bewoners met
probleemgedrag door de staf geselecteerd en 1479 bewoners werden aselect
gekozen. Psychiatrische stoornissen werden gemeten met Nederlandse versies
van de ‘Reiss Screen for maladaptive behavior’ en de ‘Psychopathology
Instrument for Mentally Retarded Adults’. Zoals verwacht, bleek de groep van
bewoners van gezinsvervangende tehuizen met gedragsproblemen veel meer
psychofarmaca te gebruiken dan de aselect gekozen groep bewoners.
Psychofarmaca exclusief anti-epileptica werden door 52,6% van de
probleemgroep gebruikt en door 22,8% van de aselect gekozen groep
bewoners. In de probleemgroep gebruikte 17,3% drie of meer psychofarmaca
tegelijkertijd en in de aselecte groep 7,3%. Door 11,1% van de probleemgroep
en 2,8% van de aselecte groep werden psychofarmaca uit drie of meer
verschillende categorieën gelijktijdig gebruikt. De prevalentie van anti-
psychotica, vaak voorgeschreven in lage doseringen en voor uiteenlopende
indicaties, was hoog (41,2% in de probleemgroep; 16,7% in de aselecte groep).
Lage doseringen van deze middelen werden waarschijnlijk voorgeschreven
omdat hiervan gunstige effecten bij verstandelijk gehandicapten met
gedragsproblemen worden beschreven. De groep van bewoners met probleem-
gedrag was significant jonger. Psychotische symptomen, symptomen van
angststoornissen en agressieve gedragingen kwamen in deze groep significant
vaker voor. Waarschijnlijk vinden groepsleiders het moeilijk deze bewoners te
begeleiden wat in overeenstemming is met de bevindingen van andere
onderzoeken. Het is opvallend dat er weinig antidepressiva, stemmings-
stabilisatoren, antipsychotica en anxiolytica werden voorgeschreven in
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bewoners met de corresponderende symptomen. Waarschijnlijk wordt een
aanzienlijk deel van de bewoners onderbehandeld.
In Hoofdstuk 4.2 wordt een onderzoek beschreven naar de prevalentie en
mogelijke determinanten van polyfarmacie bij patiënten met een lichte
verstandelijke handicap of zwakbegaafdheid en psychiatrische of gedrags-
stoornissen. Deze patiënten zijn opgenomen op een gespecialiseerde gesloten
afdeling voor langdurige behandeling en rehabilitatie. Gegevens over
psychofarmaca en factoren die daar mogelijk mee samenhangen werden
retrospectief verzameld in een groep van 96 patiënten van 16 jaar en ouder die
minstens een maand opgenomen waren tussen 1992-1997. Polyfarmacie werd
gedefinieerd als het gelijktijdig gebruik van benzodiazepines/tranquillisers/
antipsychotica/anti-epileptica/antidepressiva. Er werd een punt prevalentie
van psychofarmaca gebruik bij opname gevonden van 63,5%, een periode
prevalentie gedurende de opname van 79,2% en een punt prevalentie bij
ontslag van 69,7%. Van alle psychofarmaca werden antipsychotica tijdens
opname het meest gebruikt (66,7%), zoals dat ook in eerdere onderzoeken is
gevonden. Polyfarmacie kwam bij de helft van de patiënten voor.
Psychofarmaca werden in hoge doseringen gebruikt. Er was een tendens om
meerdere middelen tegelijkertijd voor te schrijven aan patiënten met een
opnameduur van meer dan een jaar. Daarnaast waren psychotische stoornis,
agressief, bizar, aandachtvragend gedrag en vrijheidsbeperkende maatregelen
geassocieerd met polyfarmacie. Veel patiënten hebben een uitgebreide
voorgeschiedenis van opnames in psychiatrische ziekenhuizen en
gespecialiseerde afdelingen van voorzieningen voor verstandelijk gehandi-
capten. De gevonden associatie met agressief en aandachtvragend gedrag wijst
waarschijnlijk op moeilijkheden in de begeleiding van patiënten met sociaal
ontwrichtend gedrag. Dit wordt benadrukt door de associatie van polyfarmacie
met psychotische stoornissen en komt overeen met andere onderzoeken
waarin een associatie wordt gevonden tussen zulk gedrag en antipsychotica
gebruik.
Samenvattend zijn patronen van psychofarmacagebruik onderzocht en zijn
mogelijke determinanten van het voorschrijven van deze middelen in
verschillende klinische populaties in kaart gebracht. In deze populaties gaat het
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om patiënten die zich in complexe situaties bevinden waarbij weten-
schappelijke onderbouwing van effectiviteit en veiligheid van psychofarmaca
schaars is. De onderzoeken laten zien dat observationeel farmaco-
epidemiologisch onderzoek een belangrijke rol kan spelen om de kloof tussen
wetenschappelijke bewijs gebaseerd op niet representatieve RCTs en de
klinische praktijk te analyseren.
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Altrecht hecht aan een klimaat waarin wetenschappelijk onderzoek goed
mogelijk is. Hiervoor en voor hun steun wil ik met name Armand Höppener,
voorzitter van de raad van bestuur en divisiedirecteur Henk van den Berg
bedanken. De bibliothecarissen Lujan Prinsen en Fieke Bannink hebben soms op
het laatste moment nog allerlei artikelen verzameld. Ik ben jullie daarvoor zeer
erkentelijk. De grafische afdeling van Altrecht in de personen van Ben van Selm
en Jan Roessink heeft me geweldig geholpen met het maken van dit boekje.
Lieve paranimfen Karin Fijn van Draat en Mariet Clerkx, bedankt voor alle
voorbereidingen en het spottende commentaar op mijn ‘perfectionistische
neigingen’. Beste Bas Sebus, je schilderij en mijn ‘voorkant’ zijn prachtig
geworden.
Hoewel ik trouw en loyaliteit in vriendschappen en familierelaties belangrijk
vind, heb ik dat zeker de laatste tijd niet altijd waar kunnen maken. Lieve
ouders Teun en Riet, broers Wim en Bram, schoonzussen Cornalien en Silke,
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‘schoonfamilie’ Ries, Mar, Nico en Ria, vrienden Giselle, Karin, Rianne, Irene en
Coen: jullie liefde en steun is heel belangrijk voor mij.
Lieve Bas, je hebt niet slechts een enkele regel, maar een hele boekenkast met
dankwoorden verdiend!
•157
CURRICULUM VITAE
Joost Jan Stolker was born in Amstelveen, the Netherlands, on February 20th,
1965. Following completion of his secondary education at the ‘Christelijke
Scholengemeenschap Buitenveldert’ (gymnasium ß) in 1983, he chose to study
Medicine at the Free University in Amsterdam. He was awarded his MD in 1991.
He then worked at a specialised psychiatric admission ward for the elderly at
the ‘Provinciaal Ziekenhuis Santpoort’ (Supervisor: D. Stam) and the ‘Centrale
Riagg Dienst’ in Amsterdam (Supervisor: R.A. Achilles). After studying outcome-
indicators of chronic psychiatry (Supervisor: Prof. dr F.G. Zitman) at the
Department of Psychiatry, University Hospital Nijmegen, during 1992-1993, he
specialised in psychiatry at the same hospital (Supervisor: Prof. dr F.A.M.
Kortmann). He continued his training at a specialised psychiatric clinic for the
intellectually disabled, a branch of Altrecht Institute for Mental Health Care.
Since September 1997, he has been practising as a psychiatrist at this
specialised clinic. He also then started his PhD project at the Department of
Pharmacoepidemiology and Pharmacotherapy, Utrecht University.
